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ABSTRACT 
The leishmaniasis are a group of poverty-associated diseases caused by the protozoan Leishmania spp. 
The complexity of this kinetoplastid parasite is highlighted by biological, ecological, and 
epidemiological aspects. It is endemic in more than 98 countries affecting around 12 million people. 
Approximately 20 species can be transmitted to humans by 78 species of the phlebotomine sandfly 
vector. Infected people can develop one of the several pathologies from which the most common are: 
cutaneous lesions, the disfiguring mucocutaneous disorder, and the life-threatening visceral disease. The 
final outcome is multifactorial, depending on intricate host-parasite interactions and environmental 
factors. The few chemotherapeutic options available are mostly unsatisfactory due to low efficacy, poor 
safety, emergence of parasite resistance, and other factors related to treatment (such as administration 
route, length of treatment or high costs) that are not suitable for the socioeconomic reality of affected 
populations. The current scenario demands research focused on the identification of novel effective 
therapeutics. Modern technologies enable the screening of millions of compounds, but a more predictive 
in vitro assays is still lacking. It is a common practice for a research group to target a single species, 
usually L. dovovani, the causative agent of visceral disease. Addressing a representative sample of 
viscerotropic and dermotropic species/strains of Leishmania can be useful to prioritize compounds based 
on their spectrum of activity. This work focused on the discovery of starting points for the development 
of new antileishmanials using an image-based methodology. Careful standardization was carried out 
aiming to achieve robustness and reproducibility, based on: (i) the biological model, determining the 
best condition for parasite and host cell culture, infection and drug exposure, and (ii) the image analysis 
algorithm. The multi-species high content assay was successfully established and validated to assess 
compound activity against some of the most clinically relevant dermotropic (L. amazonensis and L. 
braziliensis) and viscerotropic agents (L. donovani and L. infantum). This semi-automated assay is based 
on THP-1 macrophages infected with stationary phase promastigotes and can be virtually adapted to 
any in vitro infective species, providing the basis for the discovery of broad-spectrum antileishmanial 
molecules. A species-specific profile was observed in the general activity of libraries screenings, and a 
reduced number of compounds were active for all species. The simultaneous screening of the Pathogen 
Box library against four Leishmania species along with literature data analysis resulted in the 
identification of 12 pan-antileishmanial compounds. Although these molecules have been reported as 
anti-kinetoplastid agents, their activity against different Leishmania species had not been explored yet. 
The results obtained from this study demonstrate the potential value of including a panel of species in 
early steps of the drug discovery process, which can facilitate the prospection, validation and 
progression of more promising compounds. The species panel, together with other reported secondary 
assays, is suggested as part of a cell-based assay pipeline for Leishmania spp. aiming to empower the 
prioritization of compounds based on crucial aspects besides the physico-chemical and toxicity filters 
traditionally applied. 
  
 RESUMO 
As leishmanioses são um grupo de doenças associadas à pobreza causadas por protozoários do gênero 
Leishmania. A complexidade desse kinetoplastídeo é evidenciada por aspectos biológicos, ecológicos e 
epidemiológicos. Essas doenças são endêmicas em mais de 98 países e acometem em torno de 12 
milhões de pessoas. Aproximadamente 20 espécies de Leishmania infectam humanos e são transmitidas 
por 78 espécies de flebotomíneos. Uma vez infectados, os pacientes podem desenvolver diversas 
patologias dentre as quais as mais comuns são: leishmaniose cutânea, leishmaniose mucocutânea e 
leishmaniose visceral. Múltiplos determinantes estão envolvidos na manifestação clínica, incluindo 
complexas interações entre o parasita e o hospedeiro, além de fatores ambientais. As poucas 
farmacoterapias disponíveis são, em grande parte, insatisfatórias devido a baixa eficácia, pouca 
segurança, surgimento de resistência e outros aspectos relacionados ao tratamento (rota de 
administração, duração e custo elevado) que são incompatíveis com a realidade socioeconômica da 
população afetada. A atual conjuntura requer pesquisa focada na identificação de novas moléculas 
antileishmaniais. Devido aos avanços tecnológicos, atualmente é possível testar milhões de compostos 
de maneira contínua, entretanto, ainda é necessário o desenvolvimento de ensaios mais preditivos. É 
comum que grupos de pesquisa limitem os testes in vitro a uma única espécie, geralmente L. donovani, 
agente etiológico da doença visceral. Estabelecer ensaios com uma amostra representativa de espécies 
vicerotrópicas e dermotrópicas pode ser uma abordagem útil na priorização de compostos baseando-se 
no espectro de atividade. Este estudo objetivou a identificação de agentes antileishmaniais usando uma 
metodologia baseada em imagens. Uma padronização cuidadosa foi realizada para alcançar robustez e 
reprodutibilidade, focando em dois aspectos-chave: (i) o modelo biológico, determinando as condições 
para cultura da célula hospedeira e do parasita, parâmetros de infecção e tempo de exposição aos 
compostos; (ii) método de análise das imagens. O ensaio fenotípico foi estabelecido e validado para 
avaliar a atividade de compostos contra algumas das espécies dermotrópicas (L. amazonensis e L. 
braziliensis) e vicerotrópicas (L. donovani e L. infantum) mais relevantes clinicamente. Esse protocolo 
é semi-automatizado, baseia-se na infecção de células THP-1 com promastigotas em fase estacionária e 
tem potencial para ser adaptado a qualquer espécie infectiva in vitro, representando a base para 
descoberta de moléculas com amplo espectro. Um perfil espécie-específico foi observado na triagem de 
bibliotecas e uma quantidade reduzida de compostos foi ativa para todas as espécies. O teste da 
biblioteca Pathogen Box contra quatro espécies, juntamente com a análise da literatura, resultou na 
identificação de 12 compostos pan-antileishmaniais. Embora esses compostos terem atividade reportada 
contra kinetoplastídeos, o amplo espectro de ação contra diversas espécies de Leishmania não havia sido 
explorado. Os resultados obtidos nesse estudo demonstram o potencial da inserção de um conjunto de 
espécies nas etapas iniciais do processo de descoberta de novos fármacos, facilitando a prospecção, 
validação e progressão de compostos mais promissores. O painel de espécies, juntamente com outros 
ensaios secundários, é sugerido como integrante de um pipeline de ensaios celulares para Leishmania 
spp. objetivando a priorização de compostos baseada em aspectos cruciais além dos filtros 
tradicionalmente aplicados de propriedades físico-químicas e de toxicidade. 
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1 Introduction 
 General aspects of leishmaniasis 
Leishmaniasis encompasses a complex group of diseases categorized by the clinical 
symptomatology, where three major forms stand out: cutaneous leishmaniasis (CL), 
mucocutaneous leishmaniasis (ML) and visceral leishmaniasis (VL). The etiological agent of 
leishmaniasis is the protozoan Leishmania spp, which is transmitted by the bite of an insect 
vector, the phlebotomine sandfly. The term “cutaneous leishmaniasis” refers to a specific 
localized form, therefore “tegumentary leishmaniasis” will be used as an overall term for all 
forms of leishmaniasis involving cutaneous/mucosal tissue. 
According to WHO, human Leishmania spp. infection is endemic in more than 98 
countries; mostly in South/Central America, Africa and the Middle East. However, these 
diseases have been expanding its geographic area, mainly as a result of the increase traveling 
to and from these regions, forced displacement resulted from international conflicts, and the 
deforestation/urbanization process (WHO 2018). Apart from that, climate changes due to global 
warming are prospected to enable a northwards expansion in Europe of areas with suitable 
climatic conditions for several vector species (P. alexandri, P. neglectus, P. papatasi, P. 
perfiliewi, P. tobbi) (Koch et al. 2017). In addition, even small fluctuations in temperature, 
rainfall and humidity can affect the cycle of Leishmania spp. in sandflies and reservoir hosts, 
allowing transmission of the parasite in regions traditionally regarded as leishmaniasis-free 
(Chalghaf et al. 2018). All these factors have contributed to the increasing number of cases 
observed during the last 25 years throughout the world. The estimated world prevalence of all 
forms of the disease is 12 million, with 2 million new cases annually (1.5 million tegumentary 
pathologies and 0.5 million VL cases). The visceral disease kills about 50,000 people each year. 
It is noteworthy to mention these numbers are probably underestimated due to the under-
reporting of cases and limitations inherent to the countries’ surveillance systems (WHO 2018). 
Leishmaniasis are associated with elevated incidence rate and wide geographic 
distribution in the Central and South Americas, which contributes to variations in transmission 
cycles, reservoir hosts, sandfly vectors, clinical manifestations, response to therapy, and 
parasite diversity, with multiple Leishmania species circulating in the region. In 2016, 17 
endemic American countries reported 48,915 CL/ML cases and seven countries registered 
3,354 VL cases. Highlighting that in this period VL fatality rate has reached 7.9% and the 
percentage of CL in children under 10 years old has also reached 15.5%. Brazil is the country 
with the highest numbers of registered cases, with12,690 CL/ML cases and 3,200 VL cases 
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reported in 2016, representing 26% and 95% of the total reported cases in the continent, 
respectively (PAHO 2018).  
In most geographic areas, leishmaniasis are considered zoonotic diseases, because 
infected people are not involved in the natural transmission cycle. Thus, others mammalian 
species, along with the sandfly vectors, maintain the cycle. But in some parts of the world, no 
animal reservoir has been identified, thereby transmission is thought to occur from human to 
sandfly to human. This type of transmission is called anthroponotic, and it is typical of the L. 
donovani and L. tropica infection in the Indian subcontinent (Bern et al. 2008). 
The accurate diagnosis of human leishmaniasis is challenging. The pathological 
aspects are diverse and depend on the infecting Leishmania species and the host immune 
response. The definitive diagnosis is based on clinical inspection, followed by isolation, 
visualization, and culturing of the parasite from infected organs tissues, such as skin lesions, 
bone marrow, lymph node or spleen. The direct visualization of parasites is the reference 
standard for diagnosis, but requires trained technicians, involves invasive sampling, and has 
variable sensitivity (WHO 2012). Less invasive diagnostic methods include serologic detection 
of antibodies to recombinant K39 antigen, and amplification of Leishmania DNA by 
polymerase chain reaction (PCR) assays. On the other hand, such approaches present relatively 
high costs and cannot discriminate between active disease from past or asymptomatic infections 
(Galluzzi et al. 2018; Sundar and Singh 2018). Additionally, the rK39 rapid 
immunochromatographic test (ICT) provided high sensitivity and specificity in the Indian sub-
continent and Brazil, but showed to be less sensitive and specific in sub-Saharan Africa, 
revealing a variability in sensitivity (Bezuneh et al. 2014). 
Since there is no registered vaccine that prevents human leishmaniasis, 
epidemiological management relies on vectors and reservoirs control strategies. Approaches 
directed to the canine reservoirs (culling, vaccination, repellent impregnated dog collars) or to 
the vector (insecticide spraying, insecticide treated bed nets) are often impractical or even 
unrealistic in large urban centers. Besides, the effectiveness of such strategies is open for debate 
(Romero and Boelaert 2010). Thus, the main strategy for disease control is treatment of patients, 
primarily in anthroponotic transmission scenarios, which emphasizes the importance of early 
detection and treatment for public health purposes (Burza et al. 2018). However, leishmaniasis 
treatment lean on drugs that present major drawbacks, such as high toxicity, contraindications 
and complex administration regimens (discussed ahead, in section 1.3.) 
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 The complex biology of Leishmania spp. parasite  
Despite intensive research, several aspects of Leishmania spp. infection remain 
insufficiently understood. This is in part due to the disease several complexity levels, from the 
parasite's perplexing life cycle to the broad spectrum of clinical outcomes. 
The complexity begins by the taxonomy of Leishmania organisms. Considerable 
genetic intraspecies variability complicates classification, and no single categorization is 
generally accepted. According with Akhoundi et al., they are classified as follow: kingdom 
Protista, phylum Euglenozoa, class Kinetoplastea, subclass Metakinetoplastina, order 
Trypanosomatida, family Trypanosomatidae, subfamily Leishmaniinae, and genus 
Leishmania. Kinetoplastids are flagellated protists whose mitochondrial genome is organized 
into a complex and concatenated network of DNA maxi and minicircles, named kinetoplast 
(and thus their mitochondrial DNA is known as kDNA). According to the development of the 
parasite in the gut of sandfly (suprapylarian and peripylarian region), the genus Leishmania is 
still subdivided in two subgenera (Leishmania and Viannia, respectively). Other subgenera or 
complexes have been described (Sauroleishmania, L. enriettii complex, and Paraleishmania), 
but they are not relevant to human diseases. There are 53 different species of Leishmania from 
which about 20 have been described as pathogenic for humans. Furthermore, they are 
categorized based on geographic occurrence: Old World, for Leishmania species found in 
Africa, Asia, Middle East, Mediterranean countries, and India; and New World, for species 
found in Central and South America (Akhoundi et al. 2016). 
Leishmania has a digenetic life cycle, infecting an invertebrate (phlebotominae 
sandflies) and a vertebrate (mammals, including humans) hosts. In addition, it presents two very 
distinct stages: promastigotes (extracellular and flagellated forms found in the insect gut) and 
amastigotes (intracellular and round forms that multiply within phagocytic immune cells). An 
illustration summarizing the life cycle can be seen in Figure 1.1. Mammals are infected by the 
bite of female sandflies that regurgitate infective promastigotes during a blood meal (Sacks and 
Kamhawi 2001). Upon entering the host, promastigotes are phagocyted by phagocytic cells. 
Neutrophils are the first cells to infiltrate the site of parasite inoculation, where they engulf the 
parasites. Leishmania spp. have a variety of mechanisms to escape neutrophil killing, some 
species even resist to the microbicity associated with neutrophil extracellular trap (NET) 
formation (revised in Hurrell et al. 2016). Concomitantly, promastigotes are phagocytosed by 
macrophages, where they differentiate into amastigotes inside phagolysosomal compartments. 
The parasites may enter directly into the macrophages through receptor recognition, or may be 
transferred silently via engulfment of infected neutrophils, known as “Trojan horses” 
16 
(Gonçalves-de-Albuquerque et al. 2017; Peters et al. 2008; Ridley 1980). After successive 
multiplication, that may occur in tight individual vacuoles (most Leishmania spp.) or in large 
communal parasitophorous vacuoles (L. mexicana complex) (Moradin and Descoteaux 2012), 
amastigotes are released from macrophages and re-infect new cells, such as macrophages, 
dendritic cells, and fibroblasts. Despite the ability of Leishmania parasites to infect a variety of 
host cell types, it seems that only macrophages support replication (Bogdan et al. 2000). The 
intracellular amastigote is, therefore, the disease-causing stage of Leishmania. The mechanisms 
involved in extracellular amastigotes release is not completely elucidated, and it may occur 
through host cell rupture and release of free amastigotes or enclosed within host cell 
membranes, such as inside apoptotic blebs, without exposure to extracellular milieu (Real et al. 
2014; Rittig and Bogdan 2000; Ridley 1980). Occasionally, upon feeding on a Leishmania-
infected mammal, sandflies ingest parasites and infected cells. In the invertebrate host, the 
Leishmania life cycle is restricted to the digestive tract and involves several morphological 
forms. Primarily, the ingested amastigotes transform into procyclic promastigotes, a weakly 
motile, replicative form that multiplies confined by the peritrophic matrix (PM). Then parasites 
differentiate into nectomonad form, elongate and strongly motile promastigotes. Nectomonads 
escape the PM and attach to the microvilli in the midgut before moving to the thoracic midgut 
and stomodeal valve. Once they reach the stomodeal valve, the nectomonad promastigotes 
transform into leptomonad promastigotes, replicative shorter forms. These are responsible for 
the secretion of promastigote secretory gel (PSG), triggering the metacyclogenesis process 
(Sacks and Kamhawi 2001). New insights in the Leishmania life cycle are constantly reported. 
Until now, metacyclic promastigotes (mammalian-infective stages) have been considered a 
terminally differentiated stage inside the vector. However, a remarkable work by Serafim et al. 
recently showed that a second uninfected blood meal by infected sandflies triggers 
dedifferentiation of some metacyclic promastigotes to a leptomonad-like stage, the 
retroleptomonad promastigote. This highly multiplicative form rapidly differentiate to more 
metacyclic promastigotes enhancing the sandfly’s infectiousness (Serafim et al. 2018). 
Ultimately, Leishmania are delivered to the skin of a new vertebrate host during sandfly next 
blood feeding, thus keeping the cycle. 
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Figure 1.1 Life cycle of Leishmania spp. 1. Host infection by metacyclic promastigotes injection 
during a blood meal of sandflies 2. Neutrophils recruitment 3. Macrophages infection 4. 
Differentiation to amastigote stage 5. Multiplication in individual vacuoles (most Leishmania spp.) 
or in large communal parasitophorous vacuoles (L. mexicana complex) 6. Release of free amastigotes 
or enclosed within host cell membranes 7. Infection of new cells 8. Ingestion of parasites and infected 
cells by sandflies 9. Amastigotes differentiation in procyclic promastigotes inside sandfly digestive 
tract 10. Differentiation to nectomonad promastigotes 11. Differentiation to leptomonad 
promastigotes 12. Differentiation to metacyclic promastigotes 13. Cyclic differentiation between 
metacyclic and retroleptomonad promastigotes. 
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Once infected, the majority of humans remain asymptomatic. The progression into 
one of the different pathologies is determined by host parameters, such as genetic characteristics 
and immunological status (Blackwell et al. 2009; Sakthianandeswaren et al. 2009; Jeronimo et 
al. 2007), and parasite features, including heterogenecity in the virulence of different 
species/strains (Naderer et al. 2004). The clinical spectrum of leishmaniasis ranges from skin 
lesions (Cutaneous leishmaniasis – CL) and mucocutaneous ulcers (Mucocutaneous 
Leishmaniasis – ML) to systemic multiorgan damage (Visceral leishmaniasis – VL). The 
parasite’s thermotropism plays a role in the pathology of leishmaniasis, VL species are able to 
grow at temperatures of deep tissues and organs, whereas those causing CL/ML grow best at 
lower temperatures of superficial tissues, such as the skin (Callahan et al. 1996). 
The most frequent clinical manifestation of Leishmania spp. infections is CL, 
characterized by lesions on the patient’s skin. The lesions range from simple spontaneously 
healing to severely inflamed ulcers that heal in months or even years. Self-healing is achieved 
by a balanced immune response. CL can be further subdivided into localized, recidivans, and 
post–kala-azar dermal leishmaniasis (PKDL). Again, host-parasite interactions determine the 
course of the disease.  
In the localized cutaneous leishmaniasis there is a single or few ulcers, usually 
present in exposed areas of the body and can self-heal without treatment. Several species can 
cause these localized lesions: L. major, L. mexicana, L. tropica, L. aethiopica, among others. 
Leishmaniasis recidivans, caused by L. tropica, is a relapsing form of cutaneous leishmaniasis 
that occur at the border of old CL scars. PKDL is distinguished by appearance of lesions that 
affect the entire extension of patient's body after the clinical cure of visceral leishmaniasis 
caused by L. donovani. CL is not a life-threatening condition and severe complications are rare, 
yet its consequences may be socially and psychologically serious, because of disfiguring lesions 
and scars (Hartley et al. 2014). 
Some infections can evolve to more severe forms known as mucocutaneous 
leishmaniasis (ML) and disseminated leishmaniasis (DL). This development is caused by 
hematogenous or lymphatic dissemination of amastigotes to secondary sites and the formation 
of metastatic lesions. The underlying mechanism of metastatic leishmaniasis development 
remains largely unknown. Interestingly, despite such lesions often present very low parasite 
numbers, there is wide tissue destruction caused by exaggerated inflammatory response 
(revised in Rossi and Fasel 2018). The disseminated manifestation, commonly associated with 
L. amazonensis and L. braziliensis, is characterized by nodules located on the head, arms and 
legs, and the number of lesions can reach hundreds. In such cases, patients are often 
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unresponsive to treatments. The mucocutaneous outcome is caused predominantly by L. 
braziliensis, but may also be caused by others species, such as L. amazonensis and L. 
guyanensis. This disease mainly affects the nasal mucosa, but the palate, pharyns, and larynx 
can also be affected. In some cases, mucosal involvement may lead to destruction of the face 
structure, causing respiratory failure associated with death (Marra et al. 2014). In addition, 
presence of Leishmania RNA virus 1 (LRV1) in the cytoplasm of the parasite has recently been 
shown to influence the severity of mucosal lesions and the overall course of the disease, being 
associated with failure of first-line treatment in patients infected with L. guynensis and L. 
braziliensis containing LRV1 (Adaui et al. 2016; Bourreau et al. 2016; Brettmann et al. 2016). 
The most extreme form of the disease is the VL, caused by L. donovani and L. 
infantum (synonym, L. chagasi), being potentially lethal if not treated. Commonly referred as 
kala-azar in the Indian subcontinent, it is characterized by systemic and chronic infection, 
affecting mainly organs such as spleen, liver and bone marrow. Symptoms include anemia, 
progressive cachexia, intermittent fever, hepatomegaly and splenomegaly (Piscopo and 
Azzopardi 2007). 
There are still some rare manifestations, such as the diffuse cutaneous leishmaniasis 
(DCL) seen in anergic individuals. DCL is characterized for numerous non-ulcerated nodules 
with an abundant intracellular amastigote load, resulted from strong humoral immune response 
and weak T cell activation. This chronic disease caused predominantly by L. amazonensis does 
not heal spontaneously and is associated with incomplete response to treatment, resulting in 
frequent relapses (Scott and Novais 2016). 
Consistently, there is a causal relationship between species and clinical outcomes 
(see Figure 1.2), but this is not always the case. Dermotropic species, for instance L. braziliensis 
and L. amazonensis, have been described to cause visceral disease in individuals co-infected 
with Human Immunodeficiency Virus (HIV); conversely, viscerotropic species like L. infantum 
have been reported in cutaneous lesions (Lindoso et al. 2016). 
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Figure 1.2 Leishmania species and more often related clinical manifestation. The genus Leishmania 
has two subgenera: Leishmania and Viannia. The most frequent species in the Old and New World are 
displayed. *L. donovani is the causative agent of post–kala-azar dermal leishmaniasis (PKDL). ** In 
South Americas, L. infantum is known as L. chagasi. Adapted from (Akhoundi et al. 2016). 
The vectors and reservoirs add a further layer of complexity, their variety reflects a 
long association that equipped the parasite with unique metabolic features to maintain its 
transmission and pathogenicity. Among over 800 species of sandflies, 78 are proven vectors of 
human leishmaniasis; these include 31 Phlebotomus species (Old World) and 47 Lutzomyia 
species (New World) (Akhoundi et al. 2016). Besides, there are so many hosts of Leishmania 
parasites, showing regional and temporal variations, that only local studies involving ecological 
and parasitological analysis can determine whether an animal is playing a role as reservoir in a 
given region. In addition to humans, a wide range of wild and domestic mammals have been 
recorded as hosts and/or reservoirs of Leishmania spp (domestic dogs, sloths, opossums and 
rodents, among others). Notwithstanding, the classification into visceral and cutaneous forms, 
based on tissue tropism of Leishmania spp. in humans, cannot be applied to the infection in 
other mammals (Roque and Jansen 2014). For instance, dogs infected with L. infantum present 
mixed forms in almost every case, where parasite isolation is common even from intact skin 
(Miró and López-Vélez 2018). 
In nature, the competent vectors often display specific relationships with parasites, 
transmitting only a single or limited number of Leishmania species. However, some sandflies 
are considered permissive (or non-specific) vectors, because it is possible to experimentally 
infect them with several Leishmania spp. The association between vector-parasite generate 
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region-specific epidemiological characteristics (Sacks and Kamhawi 2001). In spite of such 
strong association, Leishmania spp. show an impressive plasticity to adapt to new vector species 
under environmental condition changes. In the Andean valleys of Chaparral, Lutzomyia 
longiflocosa was found to be the vector in L. guyanensis transmission, very different from the 
previous known vector Nyssomyia umbratilis (Ferro et al. 2011, 2015). 
 Current antileishmanial chemotherapy 
It has been more than 100 years since Gaspar Vianna tested emetic tartar to treat 
cutaneous leishmaniasis (Vianna 1912). Later on, in 1920, Upendranath Brahmachari produced 
the first organic antimonial to achieve wide acceptance as a treatment for human leishmaniasis, 
which saved thousands of lives in India (Brahmachari 1989). Since then, less toxic pentavalent 
antimonials (sodium stibogluconate and meglumine antimoniate) were produced, but they still 
require long course parenteral treatment and careful health monitoring (Chulay et al. 1988). 
Injectable pentavalent antimonials were the single regimen available to treat VL for more than 
50 years, and up to now remain a pillar of therapy for leishmaniasis, except in the Indian 
subcontinent, where they have been abandoned due to widespread resistance (Kuhlmann and 
Fleckenstein 2017). 
New drugs have been introduced in the therapeutics of leishmaniasis over time. The 
first use of Pentamidine for VL treatment was reported in India in 1949 and in Spain in 1950 
(Hazarika 1949; Martinez Garcia et al.1950). In vitro activity of amphotericin B was for the 
first time reported in 1960 and the first successful treatment of patients with VL was reported 
in 1963 in Brazil (Furtado et al. 1960; Prata 1963). In early 1990’s, the advent of the first lipid-
carrier formulation decreased acute and chronic toxic effects of deoxycholate formulation of 
amphotericin B (Gulati et al. 1998; Meunier et al. 1991). Miltefosine was identified and 
evaluated independently in the early 1980s as a potential anti-cancer drug in Germany and as a 
leishmanicidal drug in the UK; and in 2002, it was approved in India as the first oral treatment 
of VL (Croft and Engel 2006). Paramomycin was shown to be efficacious for the treatment of 
CL in 1966 and for VL in 1990 in Kenya (Chunge et al. 1990; Moskalenko and Pershin 1996).  
Against the progress achieved by the introduction of new therapeutic options, all 
current drugs present important drawbacks, such as: low efficacy, high toxicity, length of 
treatment or high cost (revised in Uliana et al. 2018). For example, miltefosine, the only 
available oral drug, is teratogenic and causes severe gastrointestinal side effects; already 
liposomal amphotericin B has intravenous administration, requires unbroken cold chain for 
distribution and is highly costly. Table 1.1 summarizes the limitations of current treatment. 
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Table 1.1Current antileishmanial chemotherapy 
Drugs Usual Regimen Administration Efficacy Resistance Toxicity Advantages Limitations 
Sodium 
stibogluconate 
and meglumine 
antimoniate 
(Pentostam® and 
Glucantime®) 
20 mg/kg/day for 
30 days 
Intravenous, 
Intramuscular or 
Intralymphatic 
Varies between 
35-95% based 
on area 
Common  
more than 
65% in Bihar, 
India 
Severe cardiotoxicity, 
nephrotoxicity, 
pancreatitis and 
hepatotoxicity 
Availability 
Confirmed resistance in Bihar, 
India 
Compliance issues (lengthy 
treatment and painful 
administration) 
Amphotericin B 
deoxycholate 
(Fungizone®) 
1 mg/kg/day for 
30 days 
Intravenous > 90% 
Laboratory 
strains 
Severe nephrotoxicity, 
thrombophlebitis and 
hypokalaemia 
Primary 
resistance not 
documented 
Heat instability 
Hospitalization for slow 
intravenous infusion 
 
Liposomal 
Amphotericin 
(Ambisome®) 
3-5 mg/kg/day for 
20 days 
Intravenous > 96% 
Not 
documented 
Mild nephrotoxicity, 
chills and fever during 
infusion 
Low toxicity, 
resistance not 
documented 
Heat instability 
High cost 
Miltefosine 
(Impavido™) 
2-2.5 mg/kg/day 
for 28 days 
Oral > 94% 
Laboratory 
strains 
Hepatotoxicity, 
nephrotoxicity and 
teratogenicity 
Oral treatment 
Long half-life encourages 
emerging resistance 
Cannot be administered to 
pregnant patients 
Paromomycin 
(Humatin®) 
15 mg/kg/day for 
21 days 
Intramuscular 
Topical 
> 94% in Asia 
and 46-85% in 
Africa 
Laboratory 
strains 
Ototoxicity, 
nephrotoxicity and 
hepatotoxicity 
Low cost 
Efficacy varies between 
different strains of Leishmania 
Potential for resistance 
Pentamidine 
(Pentacarinat®) 
3 mg/kg/day for 4 
days 
Intramuscular 
Varies between 
36-96% based 
on area 
Not 
documented 
Severe hyperglycaemia, 
Mayocarditis 
hypotension and 
tachycardia 
Short dosage 
regimen 
Efficacy varies based of 
geographical location of the 
disease 
Adapted from (Zulfiqar et al.  2017).  
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Furthermore, factors associated with low adherence of patients and treatment 
schemes not well clinically validated promote disease relapse and emergence of drug resistance, 
contributing to the therapeutic failure. The inconsistent methodologies used in clinical trials to 
assess regimens options especially hampers the progress of CL treatment standardization 
(Olliaro et al. 2018). 
In order to increase treatment efficacy, drug combination has been explored in 
leishmaniasis clinical trials. Improvement in tolerability are expected, as the two drugs can be 
administered below their individual dose limits, possibly reducing their side effects. 
Furthermore, this approach has demonstrated potential results to prevent and/or delay the 
emergence of pathogen resistance (Alirol et al. 2013; MacLean et al. 2010). Visceral 
leishmaniasis’ clinical studies using amphotericin B in combination with miltefosine or 
paromomycin have shown promising results: both combinations were well tolerated and safe, 
with cure ratios that exceeded 94% (Rahman et al. 2017). The use of pentavalent antimonial 
combined with pentoxifylline has also been proved effective against cutaneous and 
mucocutaneous leishmaniasis (Brito et al. 2017; Machado et al. 2007). Topical formulations 
combined with systemic drug may also represent an interesting option to severe forms of CL, 
as in such cases only topical or local treatment are not recommended (Uliana et al. 2018). 
Given the epidemiologic impact of leishmaniasis as well as the lack of appropriate 
treatment options, the development of safer, more effective and affordable new drug candidates 
and/or the improvement of existing therapies remains a priority. 
 The challenging Leishmania drug discovery pipeline 
Drug discovery and development is a long and complex process (see Figure 1.3). 
At the outset, basic research relies on two approaches: (i) the identification, validation and 
characterization of drug targets; and (ii) establishment of appropriate cell-based models. Then 
screening technologies allow test of libraries with novel pharmacophores to identify hits in both 
target-based and cell-based assays. Partnership between university and industry, and financial 
support are essential to maximize the number of tested samples. Such support from public-
private partnerships and interaction with the pharma/biotech sector is also important to bring 
expertise in lead optimization and preclinical studies (toxicology, pharmacokinetics and 
pharmacodynamics). Eventually, a compound is targeted to clinical trials in humans and, once 
showing a satisfactory profile, it is defined as a drug candidate. Multidisciplinary centers and 
integrated network are fundamental to trial design standardization and systematic reporting, 
making feasible the comparison of efficacy among studies with different drugs and regions. 
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The last steps of the development process include registration and manufacturing of the 
medicine. In this case, governmental policies are the responsible for an adequate drug 
legislation, and a functioning drug regulatory authority with adequate resources and 
infrastructure to enforce the legislation and regulations (revised in Alcântara et al. 2018). 
 
Figure 1.3 Drug discovery pipeline. The process often starts with basic research in order to (i) 
identify and validate molecular/biochemical targets (target-based assays) or (ii) develop and validate 
phenotypic assays (cell-based assays), which will be used to screen compounds. Medicinal chemistry 
experts will then optimize selected compounds. Next steps consist in testing candidates in animal 
models and assessing their performances by determining pharmacokinetics and pharmacodynamics 
properties. Finally, a compound is targeted to clinical trials in humans and, once showing a 
satisfactory profile, it is defined as a drug candidate. The last steps of the pipeline include registration 
and manufacturing of the medicine. The arrows show institutions that helps to integrate the whole 
process. 
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Target product profile (TPP) is defined as a planning tool for promising therapeutic 
candidates. Basically, TPP takes into account factors, such as compounds’ clinical efficacy, 
delivery mode, safety and tolerability, contraindications, dosage form, stability, treatment 
duration, and cost ( NIH 2018; Bandyopadhyay 2017). When applied properly, it can play a 
central role in drug discovery pipeline, driving both compounds progression and prioritization 
(Field et al. 2017; Wyatt et al. 2011). Table 1.2 display the optimal TPP established by DNDi 
for leishmaniasis. Overall, drug candidates should present broad-spectrum activity, in terms of 
distinct species and geographic regions. 
Table 1.2 Optimal Target product profile of new chemical entities for leishmaniasis 
 Visceral Leishmaniasis Cutaneous Leishmaniasis 
Species All species All species 
Distribution All areas All areas 
Clinical Efficacy > 95% >95%, minimal scar and no relapse 
Safety and Tolerability Should not require monitoring Should not require monitoring 
Contraindications None None 
Interactions None – Compatible for combination  None – Compatible for combination 
Formulation Oral /intramuscular depot Topical / oral 
Treatment Regimen 1/day for 10 days po/ 3 shots over 10 days Topical: 14 days; Oral: < 7 days 
Stability 3 yrs in zone 4 No cold chain, at least 3 years at 37ºC 
Cost < $10 / course US$5 
Data available at www.dndi.org, Nov, 2018 
Recently, in vitro cell-based assays have become the main screening strategy in 
drug discovery for Leishmania spp. Enzymatic-based approaches are less applied mainly 
because not many targets have been genetically or chemically validated (Jones et al. 2018). 
Additionally, there is a lack of knowledge about the exact mode of action for standard 
antileishmanial drugs, which potency seems to reflect the inhibition of multiple targets or 
pathways (Castillo et al. 2010). Although target identification is not necessarily required for 
clinical development, it does represent a key knowledge that can support optimization and 
development of back-up series, as well as the assessment of possible off-target effects and 
emergence of drug resistance. Notwithstanding, in the past few years, two promising 
antileishmanial compounds with known targets have emerged, both primarily identified by cell-
based assays. Khare et al. identified the triazolopyrimidine molecule GNF6702 as having potent 
activity against Leishmania. It acts by inhibiting the cell’s proteasomal protein-degradation 
machinery (Khare et al. 2016). Secondly, Willie and collaborators reported a potential drug 
candidate (DDD853651/GSK3186899) that inhibits the parasite protein kinase enzyme CRK12. 
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This drug showed in vitro potency and in vivo efficacy with appropriate pharmacokinetic, 
physicochemical and safety properties, being approved to human clinical trials (Wyllie et al. 
2018).  
The cell-based models evaluate compound activity based on inhibition of parasite 
multiplication and viability. There are several screening assays available against Leishmania 
spp. based on the parasite different stages: promastigotes, axenic amastigotes or intracellular 
amastigotes. As can been seen in Figure 1.4, the use of each stage has advantages and 
disadvantages (revised in Zulfiqar et al. 2017). 
 
Figure 1.4 Advantages and limitations of assays with the different stages of Leishmania spp. 
Screenings with axenic forms of Leishmania present several advantages; (i) easily 
yield sufficient number of parasites to test many compounds; (ii) faster read-outs; (iii) higher 
throughput; and (iv) reproducibility. These features are particularly attractive for initial 
screening of large sample libraries. However, Leishmania promastigotes and amastigotes 
survive and proliferate in very different environments. The parasites optimize their metabolism 
in order to utilize the available resources, which explains the observed stage-specific 
differences to drugs (Subramanian and Sarkar 2017). Siqueira-Neto et al. showed that 50% of 
the hits detected against the intracellular amastigote are not detected in the promastigote 
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screening (Siqueira-Neto et al. 2012). Still, although axenic amastigote screenings are 
performed using the clinically relevant stage of the parasite, the capacity of drug penetration in 
the host cell is not evaluated, neither is the activity in the phagolysosomal environment (acidic 
milieu). There is a high false-positive rate for the axenic amastigote assay, showing a lack of 
correlation with intracellular amastigote assays (De Rycker et al. 2013). In addition, the 
establishment of axenic amastigote cultures is not successful achieved for all Leishmania 
species (Gomes-Alves et al. 2018). Lastly, axenic assays do not allow identification of 
compounds when host cell metabolism is required for activity, or when antileishmanial capacity 
is promoted by modulation of the infected macrophages. 
Despite all drawbacks, axenic amastigote assays can be used to identify 
antileishmanial candidates, since associated with intracellular assays for further 
characterization of compounds activity. A successful example is the recent screening of 3 
million compounds against L. donovani axenic amastigotes (Khare et al. 2016). The library was 
also concomitantly screened against Trypanosoma cruzi intracellular amastigotes and 
Trypanosoma brucei bloodstream trypomastigotes. An azabenzoxazole compound, GNF5343, 
was identified as a hit in the primary screening for L. donovani and T. brucei, but not for T 
cruzi. Interestingly, the compound demonstrated anti-T. cruzi activity in secondary assays, 
which further demonstrates the difficulty to primary identification of compounds in intracellular 
models. The initial EC50 value of GNF5343 against L. donovani intracellular amastigotes was 
7.3 µM. Its chemical optimization, focused on improving bioavailability and potency on 
inhibition of L. donovani growth within macrophages, led to the discovery of a more potent 
analog: GNF6702 (EC50 of 18 nM). The GNF6702 was able to clear parasites from mice in all 
three models of infection. Further studies identified GNF6702 as a selective inhibitor of the 
kinetoplastid proteasome (Khare et al. 2016). 
The intracellular amastigote assay of Leishmania spp. is recognized as the more 
representative model for drug discovery. Because beyond the activity against the amastigote 
stage, the ability of crossing multiples membranes and stability in the parasitopharous vacuole 
acid milieu (pH 5.5) is evaluated. The main drawback is the low rate of active compounds, for 
reasons that are not well understood, but may be partially explained by slow replication of 
intracellular amastigotes (Tegazzini et al. 2016). The reported in vitro intracellular models 
involve primary isolated macrophages as host cells (mouse peritoneal macrophages, mouse 
bone-marrow-derived macrophages or human blood monocyte-derived macrophages), murine 
cell lines (Raw 264.7 and J774A.1) or human-monocyte transformed macrophages cell lines 
(THP-1, U937, and HL-60). The activity of tested drugs is measured by microscopic counting 
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of infected cells and number of amastigotes per macrophage or by colorimetric/fluorimetric 
methods (Croft et al. 2006). Thus, there are several cell-based assays, making it complicated to 
compare screening data between different laboratories using distinct screening methods. A 
common denominator for comparison of different protocols would be the level of activity of 
reference drugs, which should, theoretically, perform similarly. However, the in vitro activity 
of antileishmanial drugs has been reported as host-cell dependent (Seifert et al. 2010), and 
variation in Leishmania species sensitivity is extensively described (Morais-Teixeira et al. 
2011; Escobar et al. 2002; Yardley and Croft 2000). 
In the intracellular amastigote assays context, High Content Screening (HCS) has 
been highlighted. The HCS methodology is based on automated imaging followed by analysis 
and data extraction by a software (Lansing et al. 2007). This setup enables qualitative and 
quantitative systematic evaluations of varied cellular phenomena (for example, absence or 
reduction of parasites in host cells), being used to measure compound activity. In this case, all 
potential targets are exposed to tested compounds, thereby increasing the probability of finding 
active compounds with different modes of action. Since the description of the first HCS assay 
for intracellular amastigote (Siqueira-Neto et al. 2010), several protocols have been stablished. 
The differences are based on the host cells type, parasite stage used to infect cells 
(promastigotes or amastigotes), periods of incubation and the fluorophores used for detection 
(Tables 1.3 and 1.4). 
Among the limitations of HCS approaches, when compared to fast-reading assays 
(colorimetric/fluorescent/luminescent), are the need of data storing and management capacity, 
and the relatively low speed of HCS data acquisition and analysis, which has been constantly 
improved by HCS systems manufacturers. Considering its complex cellular models and higher 
sensitivity to micro-environmental variations (mechanical forces and thermic oscillation), cell-
based assays also tend to present lower reproducibility when compared to target-based assays 
(Moraes and Franco 2016).  
Despite the limitations, HCS of intracellular amastigote remain the benchmark for 
Leishmania drug discovery. This is mainly because HCS technologies also permits the early 
assessment of potential toxicity against the host cells, and morphological changes examination 
that can provide useful information to understand the mode of action of the compounds of 
interest. In addition, HCS association with High Throughput Screening (HTS), miniaturized 
and totally automated assay version, makes it possible to screen thousands of compounds in a 
single run (Zanella et al. 2010).  
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Table 1.3 HCS assays reported for Leishmania spp.: general biological parameters 
Reference Species 
AMB 
pEC50 
Parasite culture medium Parasite stage Cell MOI 
Treatment 
period 
(Gomes-Alves et 
al. 2018) 
L. infantum 
(MHOM/MA/67/ITMAP-263)  
7.4 RPMI 1640 10% FBS Axenic amastigotes BMDM, BALB/c 10 24 h 
(Gomes-Alves et 
al. 2018) 
 L. amazonensis 
(MHOM/BR/LTB0016) 
7.4  Schneider's 10% FBS Stationary promastigotes BMDM, BALB/c 10 24 h 
(Eren et al. 2018) 
L. guyanensis 
(MHOM/BR/75/M4147) 
6.6 Schneider’s 20% FBS Stationary promastigotes BMDM, C57BL/6 10 48 h 
(Duffy et al. 
2017) 
L. donovani 
(MHOM/IN/80/ DD8) 
6.5 M199 10% FBS Stationary promastigotes THP-1 5 96 h 
(Tegazzini et al. 
2016) 
L. donovani (MHOM/SD/62/1S-
CL2D, LdBOB) eGFP 
7.2 
Specifc media decribed 
in (Goyard et al. 2003) 
Axenic amastigotes THP-1 10 96 h 
(Dagley et al. 
2015) 
L. mexicana  
(MNYC/BZ/62/M379) 
6.3 RPMI 1640 10% FBS Axenic amastigotes THP-1 10 96 h 
(Aulner et al. 
2013) 
L. amazonensis DsRed2 
(MPRO/BR/1972/M1841, LV79)  
6.8 - 
Amastigotes freshly 
purified from lesions  
BMDM, BALB/c 3 72h 
(De Rycker et al. 
2013) 
L. donovani eGFP 
(MHOM/SD/62/1S-CL2D, LdBOB)  
6.7 
Specifc media decribed 
in (Goyard et al. 2003) 
Axenic amastigotes THP-1 5 72h 
(De Muylder et 
al. 2011) 
L. donovani 
 (MHOM/SD/62/1S-cl2D) 
7.1 
RPMI 1640 10% FBS and 
10% Brain Heart Tryptose 
Stationary promastigotes THP-1 15 72h 
(Siqueira-Neto et 
al. 2010) 
L. donovani  
(MHOM/ET/67/HU3) 
6.5 M199 10% FBS Stationary promastigotes THP-1 50 96 h 
pEC50 = -log EC50 (M) 
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Table 1.4 HCS assays reported for Leishmania spp.: imaging and analysis 
Reference Assay format Staining 
Mangnification/ 
Nº images per well 
Image acquisition system/ 
analysis software 
Number of tested 
compounds 
(Gomes-Alves et 
al. 2018) 
96-well 
DAPI, CellMask Deep Red and antibody 
against Leishmania Alexa Fluor 568 
20X/ 4 images 
IN Cell Analyzer/ 
Investigator or CellProfiler 
Only reference 
compounds 
(Gomes-Alves et 
al. 2018) 
96-well 
DAPI, CellMask Deep Red and antibody 
against Leishmania Alexa Fluor 568 
20X/ 4 images 
IN Cell Analyzer/ 
Investigator or CellProfiler 
Only reference 
compounds 
(Eren et al. 2018) 96-well DAPI and phalloidin-Alexa488 40x/ 49 images 
MetaXpress and 
AcquityEpress 
1,280 
(Duffy et al. 
2017) 
384-well SYBR green/ CellMask Deep Red 20X/ 4 images Opera / Acapella 400 
(Tegazzini et al. 
2016) 
384-well DAPI/ eGFP 20x/ 4 images Opera QEHS/ Acapella 176 
(Dagley et al. 
2015) 
384-well 
DAPI, CellTracker Green (CMFDA) and 
CellTracker Orange CMRA 
20x/ 25 images 
Cellomics ArrayScan 
VTI/Cellomics 
Colocalization V4 
BioApplication 
Only reference 
compounds 
(Aulner et al. 
2013) 
384-well Hoechst 33342 and LysoTracker DND-26 10x/ 15 images Opera QEHS, Acapella 60 
(De Rycker et al. 
2013) 
384-well DAPI, HCS Cellmask Deep Red/eGFP 10x/ no reported 
IN Cell Analyzer 1000 or 
2000/ Investigator 
15,659  
(De Muylder et 
al. 2011) 
96-well DAPI 20x/ 8 images 
INCell Analyzer 1000/ INCell 
Developer Toolbox 1.7 
909 
(Siqueira-Neto et 
al. 2010) 
384-well Draq5 20x/ 4 images 
Opera/ Image Mining (IM) 
software in-house. 
26,500 
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As can be observed in Table 1.3, the THP-1 macrophages have been widely applied 
in HCS assays. THP-1 is a human monocyte-like cell line, derived from the peripheral blood of 
a childhood case of acute monocytic leukemia (Tsuchiya et al. 1980). They need to be activated 
to induce differentiation into macrophage-like cells. Phorbol 12-myristate 13-acetate (PMA) 
and 1 α, 25-dihydroxyvitamin D3 (VD3) are two common activators for THP-1, after 
stimulation cells become adherent, acquire morphological features of macrophage-like cells, 
upregulate phagocytic receptors and stop proliferation (Schwende et al. 1996; Tsuchiya et al. 
1982). Although PMA is not a substance endogenously produced in the host, PMA-stimulated 
differentiation generates cells more similar to macrophages derived from human peripheral 
blood mononuclear cell (PBMC) (Schwende et al. 1996). However, little is known about the 
PMA mechanism responsible for regulating this differentiation process, but there is evidences 
that the phosphoinositide-3-kinase/AKT (PI3K/AKT) signaling pathway is involved (Zeng et 
al. 2015). Surprisingly, THP-1 cells do not respond to macrophage colony-stimulating factor 
(M-CSF), a potent a hematopoietic growth factor that regulates functional activation of 
monocytes, but rather internalize and degrade it very quickly (Datta et al. 1992). Once 
differentiated (M0 macrophages), they can be incubated with IL-4 and IL-13 in order to obtain 
M2 polarized macrophages or with IFN-gamma and LPS for classical macrophage activation 
(M1) (Genin et al. 2015). Additionally, THP-1 cells are rapidly differentiated into mature 
dendritic cells (DCs) when cultured in serum-free medium containing granulocyte-macrophage 
colony-stimulating factor (GM-CSF), tumor necrosis factor-α (TNF-α) and ionomycin (Berges 
et al. 2005). The differentiation process is summarized in Figure 1.5.  
 
Figure 1.5 Differentiation of THP-1 cells. These monocytes-like cells can be stimulated 
toward macrophage or dendritic cell phenotypes. After incubation with specific activators, 
there are cellular effects on morphological, phenotypical, molecular and functional properties. 
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There has been a great engagement of screening research groups, allowing the 
identification of new active, selective and bioavailable compounds, which are now progressing 
into the development pipeline (DNDi 2016). However, the path to be followed by a new 
chemical entity from discovery to registration is a long and costly process, there are high 
attrition throughout the pipeline, causing downstream failures of most candidates. As in the 
case of VL-2098, a molecule identified by DNDi as very potent and safe, being selected for in-
depth evaluation of its efficacy, pharmacokinetic, and early safety profile (Gupta et al. 2015). 
Later on, it was observed that VL-2098 causes testicular toxicity in mice models and therefore 
a decision was made to stop development of this drug (DNDi 2015).  
High quality compound collections can be composed by: fully synthetic molecules; 
naturally-occurring bioactive small molecules, derivate from natural products (extracts from 
plants, animals, microbes and minerals); and semi-synthetic molecules, hybrids of natural and 
synthetic sources. In vitro drug screening, regardless of the library composition, may select 
candidates for new drugs. The two new promising antileishmanial compounds, GNF6702 and 
DDD853651/GSK3186899, were identified from synthetic libraries (Wyllie et al. 2018; Khare 
et al. 2016). Leishmaniasis chemotherapy has been historically associated with natural products 
(revised in Rodrigues et al. 2015). Amphotericin B is extracted from the filamentous bacteria 
Streptomyces nodusus and paromomycin is extracted from Streptomyces rimosus (Rodrigues et 
al. 2015). The identification of natural products with antileishmanial activity is constantly 
reported, such as artemisinin and lissoclinotoxin E (Zulfiqar et al. 2017; Sen et al. 2010). 
However, the identification of a new molecular scaffold, also known as de novo drug discovery, 
is high cost and time-consuming. Thus, drug repurposing has been considered as a powerful 
approach to accelerate the process of novel candidates’ identification and optimization. Several 
antileishmanials were primarily indicated for others pathologies: amphotericin B, pentamidine 
and paromomycin (revised in Charlton et al. 2018). Despite the often assignment of miltefosine 
as a repurposed medicine to leishmaniasis, the discovery of its antiprotozoal and antineoplastic 
activities occurred simultaneously but independently (Croft and Engel 2006). However, priority 
was given first to the development of miltefosine as a treatment for cancer, which highlights 
the negligence toward leishmaniasis. Drug repurposing continuously identify new 
antileishmanials, noteworthy, the example of tamoxifen. Tamoxifen is a broad spectrum 
antileishmanial with activity against clinical isolates from CL and VL patients (Miguel et al. 
2011, 2009, 2007). Figure 1.6 shows the compounds exemplified here for each approach. 
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Figure 1.6 Drug discovery approaches. Examples of leishmnanial 
compounds for each category are shown. Current therapy is highlighted in red.  
The use of animal models is still necessary to establish anti-protozoan activity, 
pharmacokinetic properties (absorption, distribution, metabolism, excretion- ADME) and 
safety profiles. Due to the complex pathophysiology of human leishmaniasis, developing and 
validating a relevant animal model is challenging. Hamsters are recognized as a promising 
model for VL, notably for L. donovani, as they mimic features of human visceral leishmaniasis 
showing progressive increase in parasite burden, cachexia, hepatosplenomegaly, pancytopenia, 
hypergammaglobulinaemia and ultimately death (Garg and Dube 2006). Post-kala-azar dermal 
leishmaniasis (PKDL) is a complication associated with VL caused by L. donovani and for 
which there is no animal model of infection established. Regarding CL, there are several species 
causing different clinical manifestations, which brings complexity to the establishment and 
validation of models with features similar to humans with respect to etiology, pathophysiology, 
symptomatology, and response to the therapeutic or prophylactic agents. Therefore, there is no 
validated animal model for CL (Mears et al. 2015). 
The inconsistency observed in activity translation of compounds from in vitro to in 
vivo assays, as well from animal models to clinical research, is a major scientific gap in 
Leishmania spp. drug discovery. Improved translation might result from validation of more 
representative animal models. 
Unfortunately, most of the compounds do not reach the clinical stage. A recent 
systematic review identified 145 published visceral leishmaniasis clinical trials from 1983 to 
2015, with data from ~27k patients. Only 0.75% (203 patients) were enrolled in studies with 
other drugs excluding pentavalent antimonial, amphotericin B deoxycholate, miltefosine, 
amphotericin B lipid-associated formulations, paromomycin, pentamidine or sitamaquine 
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(Bush et al. 2017). Notwithstanding the current Public – Private – Partnerships (PPP) initiatives 
(revised in Alcântara et al. 2018), which combine academic knowledge and pharma/biotech 
expertise in an efficient modus operandi network addressing all aspects of Leishmania drug 
discovery, no drug candidate fulfilling DNDi target product profile has been forwarded to 
clinical evaluation so far. 
Once a molecule is defined as a drug candidate, it seems the most challenging steps 
have been trespassed (discovery, design, synthesis and clinical trial). However, a whole world 
of flaws arises: regulatory approval and commercialization. The drug must be manufactured 
according to high standards of purity and stability as established by regulations. In last instance, 
commercial price and supply strategies must assure availability. Miltefosine is an example of 
successful research and development (R&D) for a neglected tropical disease (NTD) that fails 
to reach the target population. The medicine price is not affordable for the majority of patients, 
most of them poor and marginalized. And even when provided for free by the public health 
system in the Indian subcontinent, the supply of the drug never quite met the demand. 
Furthermore, lack of the active pharmaceutical ingredient in generic capsules has been reported 
in Bangladesh (Sunyoto et al. 2018). 
 Cutaneous leishmaniasis: neglected within neglected tropical diseases 
Neglected Tropical Diseases (NTD`s) are a group of infectious diseases which 
affect over one billion people globally, predominantly tropic and sub-tropic regions, but despite 
such scope, treatment options are partly investigated. The most affected people are the poorest 
population due to malnutrition, population displacement and lack of access to safe water, 
sanitation and basic health services. Therefore, pharmaceutical industry and academia present 
minor interest in this field because such diseases do not represent a substantial profitable 
market. Accordingly with the 10th meeting of the Strategic and Technical Advisory Group for 
Neglected Tropical Diseases, the World Health Organization (WHO) lists 20 poverty related 
diseases, including leishmaniasis (WHO 2017). 
Due to the limited resources available for the development of new drugs against 
neglected diseases, for many years cutaneous leishmaniasis (CL) was not part of the research 
and development (R&D) agenda of most foundations, partnerships or the industrial sector. 
Correspondingly, the scientific community has focused on the screening of compounds against 
visceral species, considering its higher mortality rate. This scenario started to change after the 
creation of the Drugs for Neglected Diseases initiative (DNDi) in 2003 and subsequent 
inclusion of all types of CL in the target diseases list in 2007 (Modabber et al. 2007). Although 
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CL is associated with low mortality, it causes very severe disfiguring scars in infected 
individuals, which most often leads to stigmatization. Such scars can be considered, in some 
societies, indicatives of low social status, further enhancing stigma. In a worse scenario, when 
leishmaniasis is believed to be contagious, infected individuals can be prevented from attending 
school, reinforcing the vicious cycle of disease and poverty (Alvar et al. 2006).  
There are substantial differences in cell biology, biochemistry and immune 
response among Leishmania species, generating the wide spectrum of clinical manifestations. 
Apart from that, it is more likely that no single chemotherapy will be suitable for all species, 
which is evidenced by reference drugs variable efficacy depending on the clinical form and 
geographical location. Therefore, a species-specific approach should be considered. The lack 
of satisfactory therapeutic agents has prompted the engagement of pharmaceutical companies 
and research institutes in screening of millions of samples on cell-based systems trying to 
identify new chemical series for visceral leishmaniasis (Khare et al. 2016; Peña et al. 2015). 
By contrast, still, few screenings of large compound collections with novel chemical classes 
have been reported for cutaneous leishmaniasis species, which was one of the underlying 
driving motivations for this project.   
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2 Objectives 
The purpose of this study was to establish a High Content Screening (HCS) assay 
for different Leishmania species and, in doing so, evaluate the impact of species-specificity in 
compound selection. 
The specific aims of the present work were as follows: 
• Development of a protocol for image analysis using commercial softwares; 
• Establishment of the intracellular assay conditions for dermotropic species; 
• Validation of the HCS assay for dermotropic species by evaluating the 
activity of a commercial library and widely used reference drugs, 
amphotericin B and miltefosine; 
• Screening of two libraries (LOPAC and Pathogen Box) for dermotropic and 
vicerotropic species of Leishmania, followed by correlation analysis of 
selected compounds between species; 
• Identification of pan-antileishmanial compounds. 
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3 Material and methods 
Unless otherwise specified, all experimental conditions in 384-well plates were 
tested in at least 16 well-replicates per independent experiment. Dose-response curves are 
assessed in triplicates. 
 Cell lines and parasite lineages 
The THP-1 cell line is a human monocytic cell line, derived from the peripheral 
blood of a human male child with acute monocytic leukemia. It is maintained in suspension and 
becomes adherent upon differentiation into macrophage-like cells. The differentiation process 
was induced by phorbol-12-myristate-13-acetate (PMA). The present cell stock was acquired 
from the Rio de Janeiro Cell Bank, Xerém-RJ, Brazil.  
Raw 264.7 is a murine leukemia adherent macrophage cell line established from a 
tumor induced by the Abelson murine leukemia virus. This cell was kindly donated by Prof. 
Dr. André G. Tempone, Center for Parasitology and Mycology Institute Adolfo Lutz, Secretary 
of Health of São Paulo State. 
J774A.1 is a murine adherent macrophage cell line derived from a tumor in a female 
BALB/c mouse. This cell line was donated by Prof. Dr. André G. Tempone, Center for 
Parasitology and Mycology Institute Adolfo Lutz, Secretary of Health of São Paulo State. 
L. amazonensis strain MHOM/BR/1977/LTB0016, L. braziliensis strain 
MHOM/BR/75/M2903, L. major strain MHOM/SU/73/5-ASKH and L. infantum 
MHOM/BR/2002/LPC-RPV were obtained from the Leishmania collection of Fundação 
Oswaldo Cruz, Rio de Janeiro – RJ, Brazil (“Coleção de Leishmania do Instituto Oswaldo Cruz 
–CLIOC”). L. donovani (MHOM/IN/80/DD8) promastigotes were kindly provided by Prof. 
Silvia Uliana – USP, Brazil. These Leishmania strains were maintained in vitro as 
promastigotes. Their infectivity in vivo was not tested. 
All cultures were routinely screened for mycoplasma contamination using 
MycoAlertTM Mycoplasma Detection Kit (Lonza). 
 Animals  
Female mice of 8 to 12-week-old balb/c strain were used. The animals were kept 
without water or dietary restriction, in light/dark cycles under a temperature of 22 to 25 °C, in 
the experimental room of the Department of Parasitology UNICAMP. The experiments with 
animals were performed in collaboration with Prof. Danilo Ciccone in the Infection Biology 
Studies lab _ LEBIL. The protocol for the use of animals was approved by the Committee on 
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Ethics in the Use of Animals (CEUA), registered under N°. 4047-1 for use of animals under 
experimentation, 10/26/2015 (See Annex I and II). 
 Reference compounds 
Stock solutions of amphotericin B and miltefosine (Sigma- Aldrich) were prepared 
by dissolving standardized powder in 100% dimethyl sulfoxide (DMSO) at 20 mM. VL-2098 
was provided by DNDi, and a stock solution of 20 mM was prepared in 100% DMSO. Aliquots 
were stored at – 20°C, under low-humidity conditions, and protected from light.  
 LOPAC library 
LOPAC®1280 were purchased from Sigma- Aldrich. The library was acquired 
dissolved in 100% dimethyl sulfoxide (DMSO) at a stock concentration of 10 mM and was 
stored at – 20°C, under low-humidity conditions, and protected from light. At first, the LOPAC 
library was tested at the single concentration of 50µM. For potency determination of selected 
compounds, cherry picking was performed, followed by confirmatory dose-response studies. 
 Pathogen Box library 
The library contains 400 molecules and is provided dissolved in 100% dimethyl 
sulfoxide (DMSO) at a stock concentration of 10 mM. The four 96-well plates were manually 
reformatted into 384-well plates and compounds were 2.5-fold diluted in 100% DMSO to final 
concentration of 4 mM. The library was kept frozen at – 20 °C, under low-humidity conditions, 
and protected from light. The Pathogen box library was tested at single-point concentration of 
20 µM. 
 Leishmania spp. culture 
Unless otherwise stated, Leishmania spp. promastigotes were cultured in M199 
media supplemented with Hepes (40 mM), adenine (0.1 mM), biotin (1 μg/mL), hemin (25 
μg/mL), L-glutamine (2 mM), 10% FBS (20% for L. braziliensis), penicillin G (100 U/mL) and 
streptomycin (100 µg/mL). Parasites were passaged at 5 x 106/mL every 2 to 3 days in T25 or 
T175-flasks and maintained at 26 °C under constant agitation (30 rpm). 
At the infection day, promastigotes parasites from 6-day old (or 5-day/7-day old, 
when specified) cultures were counted, centrifuged (pelleted) at 2,200 x g for 5 min, 
resuspended and diluted to the correct density in RPMI 1640 media. The infection was 
performed with 50 promastigotes per cell (or 10/20/40, when specified) by adding 25 μL of the 
promastigote suspension in each well. The plates were incubated at 37 °C (34 °C for cutaneous 
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species), in a 5% CO2 humidified incubator for 24h prior treatment with compounds. 
 
 Raw 264.7 and J774A.1 cell lines culture 
Raw 264.7 and J774A.1 cell lines were maintained in RPMI 1640 medium 
supplemented with 10% of heat-inactivated Fetal Bovine Serum (FBS), Hepes (10 mM), 
sodium bicarbonate (1.5 g/L), sodium pyruvate (1 mM), penicillin G (100 U/mL) and 
streptomycin (100 µg/mL). at 37°C in a 5% CO2 humidified incubator. Subcultures were 
prepared washing the cells twice with PBS, followed by the addition of trypsin for 5 minutes, 
then dilution in completed medium and thoroughly re-supension. The cells were counted and 
then plated at density of 1x105/mL or at ratio of 1:10 every 3 to 4 days in T75 flasks. 
 Culture of L929 cells and recovery of supernatant 
L929 cell line secretes macrophage colony stimulating factor (M-CSF), an 
important factor for the differentiation of bone marrow derived macrophages. In order to obtain 
their supernatant, the cells were cultured in 15 mL of RPMI 1640 medium, supplemented with 
10% FBS, in a 75 cm2 flask. The flask was maintained at 37 °C in the presence of 5% CO2 for 
7 days or until reaching maximum confluency. After, the culture was washed twice with PBS, 
followed by the addition of 3 mL 0.05% trypsin for 5 minutes at 37 °C to detache the cells. The 
reaction was blocked by adding 7 mL of RPMI 1640 medium supplemented with 10% FBS, 
stopping the action of the enzyme. Cells were resuspended and divided into 20 cell culture 
flasks of 175 cm2 containing 40 mL of RPMI 1640 medium, supplemented with 10% FBS. 
After 14 days at 37 °C in the presence of 5% CO2, the culture supernatant was collected, 
centrifuged at 524 x g for 10 min, filtered in a 0.2 μm filter and stored in aliquots at -20 °C until 
use. 
 BMDM isolation 
Bone marrow-derived macrophages (BMDMs) were isolated from femurs of 
female BALB/c mice, as described previously (LUTZ et al., 1999; CORTEZ et al., 2011). 
Briefly, the mice were euthanized in a CO2 chamber. The femurs and tibias were then 
withdrawn and immersed in 70 ° GL alcohol for 2 min, followed by immersion in PBS. 
Afterwards the two epiphyses were cut off and the bone flushes with 5ml RPMI 1640 medium. 
The flow-through was then collected. The cell suspension was centrifuged at 230 × g for 10 
min at 4 ° C and next resuspended in RPMI 1640 medium supplemented with 20% of heat-
inactivated Fetal Bovine Serum (FBS), Hepes (10 mM), sodium bicarbonate (1.5 g/L), sodium 
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pyruvate (1 mM), penicillin G (100 U/mL), streptomycin (100 µg/mL) and 20% of L929 cell 
supernatant. Cells were cultured in cell culture dishes of 100 mm in diameter at 4 × 106 cells in 
10 mL of medium and incubated at 37 °C for 4 days in the presence of 5% CO2. On the fourth 
day a further 10 mL of RPMI 1640 medium supplemented with 20% FBS and 20% supernatant 
of L929 cells were added to the plate. On the seventh day of culturing, adhered macrophages 
were detached by scraping with a cell scraper and used for assays. Cell viability was assessed 
using trypan blue (0.04 %) and a hemocytometer (Neubauer chamber). The plating was 
performed in 384 well plates at the density of 7,500 cells per well and maintained at 37 ° C for 
24 hours prior to infection. 
 THP-1 culture and differentiation 
THP-1 cells were cultured in RPMI 1640 medium supplemented with 20% of heat-
inactivated Fetal Bovine Serum (FBS), Hepes (10 mM), sodium bicarbonate (1.5 g/L), sodium 
pyruvate (1 mM), penicillin G (100 U/mL) and streptomycin (100 µg/mL), at 37 °C in a 5 % 
CO2 humidified incubator. Cells were seeded at 2 x 105/mL every 3 to 4 days in T-flasks and 
maintained in exponential growth up to 10 passages, after which the batch was discarded and a 
new culture was started from a frozen culture stock. The cellular density cannot exceed 1 × 
106/mL. 
THP-1 cells were differentiated from monocytes to macrophages 4 days after 
passaging in culture flasks. Unless otherwise noted, cells were washed once in RPMI media 
and plated onto 384 well plates (F-bottom, μCLEAR®, black, Greiner Bio-One—cat. no. 
781091) at 7,000 cells/well in 25 μL of RMPI media containing 50 ng/mL PMA, and incubated 
at 37 °C/5 % CO2 for 48 h before infection. 
 Intracellular amastigotes assay 
THP-1 cells were plated onto assay plates (7,000 cells/well, 50 μL) in RPMI media 
(50 ng/mL PMA), and incubated at 37 °C/5 % CO2 for 48 h. Then, cells were infected with day-
6 promastigotes at a multiplicity of infection (MOI) of 50 by adding 25 μL of RPMI (without 
PMA) containing 1.4x107 parasites/mL, thus decreasing PMA concentration to 25 ng/mL. After 
24h of incubation at 37 °C (34 °C for cutaneous species), 10 μL of compounds were added to 
the plate, as well as 10 μL of the negative control-vehicle (0.5% DMSO) and the positive control 
(10 μM amphotericin b), according to a plate map. For dose-response curves, ten-points of serial 
dilution by a factor of 2 were tested. After 96h of compound exposure at 37 °C or 34 °C, plates 
were fixed with 4% paraformaldehyde (PFA) in PBS pH 7.4 and washed three times with PBS. 
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Following fixation and washing, plates were stained with 5 μM Draq5 in PBS, and processed 
for image analysis. The sequential steps are represented in Figure 3.1. 
 
Figure 3.1 Intracellular amastigotes assay protocol. 
 High content image acquisition and data analysis 
Four images from each well were acquired in the Operetta High Content Imaging 
System (PerkinElmer), version 3.1, or in the InCell Analyzer High Content Imaging System 
(GE), version 2200, using a 20x objective and filters optimized for far-red fluorescence 
(fluorescence filter: 635nm). 
Next, images were analyzed by Harmony (PerkinElmer) or Investigator (GE) 
software, providing the following outputs: total number of cells, total number of infected cells, 
number of parasites (spots) per infected cell, the ratio of infected cells to the total number of 
cells, this is the Infection Ratio (IR), in all 4 images from a given well. The tables 3.1 and 3.2 
display the parameters used for each software. The parameters values in the tables are mean 
values obtained for all species under the experimental conditions here described, each 
parameter was fine adjusted to optimize parasites detection for each specie. These values 
change according with the image objective, time of exposure, quality of the image. 
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Table 3.1 Parameters of Harmorny software 
Analysis steps Parameters Parameter value 
Find nuclei (method B) 
Common Threshold 0.50 
Area >55µm2 
Split factor 14.0 
Individual Threshold 0.65 
Contrast > 0.20 
Find cytoplasm 
(method B) 
Common threshold 0.35 
Individual threshold 0.15 
Select population I Common filters Remove the border objects 
Find spots (method C) 
Radius ≤1.43 
Contrast >0.13 
Uncorrected spot to region intensity >0.90 
Distance ≥1.20 
Spot peak radius 0.00 
Select population II Filter by property Number of spots ≥ 1 
Define results 
Sets which information will be 
provided from image analysis. 
Total cell number, Infected cells 
number, and total spots number 
 
Table 3.2 Parameters of Investigator software 
Analysis steps Parameters Parameter value 
Nuclei 
Segmentation Top-hat 
Minimum area 80 µm2 
Sensitivity 85 
Cells 
Segmentation Collar 
Radius 15.6 
Organelles 
Segmentation Multiscale top-hat 
Granule size 1.2-3 
#Scales 1 
Sensitivity 85 
Detect inclusions In the cytoplasm 
Advanced _ sensitivity range 3.5 
Summary 
Sets which information will be 
provided from image analysis. 
Total cell number, Infected cells 
number, and total spots number 
 
To determine the normalized antileishmanial activity (NA), the raw data of 
infection ratio (IR) for the samples (S) was normalized to the IR mean of negative controls 
(NC), meaning 0.5% DMSO-treated infected cells, which is the concentration found in each 
well when compounds are added; and the IR mean of positive controls (PC), that is non-infected 
cells treated with 0.5% DMSO. Data normalization is performed per plate. NA is expressed as 
a percentage of activity in comparison to control wells, according to the equations below: 
 
 
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝐴𝑐𝑖𝑡𝑖𝑣𝑖𝑡𝑦 = [1 − (
 𝐼𝑅(𝑆) − 𝑚𝑒𝑎𝑛 𝐼𝑅(𝑃𝐶)
𝑚𝑒𝑎𝑛 𝐼𝑅(𝑁𝐶) − 𝑚𝑒𝑎𝑛 𝐼𝑅(𝑃𝐶)
)] × 100 
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Normalized Activity values were processed with the Graphpad Prism software, 
version 6, for generation of sigmoidal dose-response (variable slope) nonlinear curve fitting. 
Potencies were expressed as pEC50, which is the negative log of the EC50 value in molar [pEC50 
= -log EC50 (M)]. For the purpose of this study, pEC50 values were determined by interpolation, 
and EC50 defined as the compound concentration corresponding to 50% normalized activity 
after 96h of compound incubation. The pEC50 is the better option to evaluate and compare 
potencies, since the curve fitting actually solves for the logEC50, not EC50. The standard error 
for pEC50 are symmetrical (pEC50 8.0 ± 0.6). Already EC50 values reported as molar values are 
on a linear scale, and the error becomes asymmetric, which may be confusing (10nM ± 30nM 
would mean EC50 ranges from -20nM to 40nM). The more potent the compound gets, its pEC50 
increases (Murray 2013). Table 3.1 exemplify the correspondence between EC50 and pEC50 
values. 
Table 3.3 EC50 and pEC50 values 
EC50 EC50 (M) pEC50 
1 nM 10-9 9.0 
10 nM 10-8 8..0 
30 nM 10-7.5 7.5 
100 nM 10-7 7.0 
1 µM 10-6 6.0 
10 µM 10-5 5.0 
30 µM 10-4.5 4.5 
100 µM 10-4 4.0 
1 mM 10-3 3.0 
10 mM 10-2 2.0 
The number of THP-1 cells are used for preliminary toxicity determination, named 
cell ratio (CR). The ratio between the total cell number in each sample (S) well and the mean 
cell number in the negative controls (NC), meaning 0.5% DMSO-treated infected cells, is 
calculated (see equation below). As closer to 1, there was no cell toxicity, comparing to control. 
Below 1 indicates a decrease in cell number, and above 1 suggest a relative increase in cell 
survival. The cell ratio values above 0.5 were considered acceptable.  
 
 
 
Plates were also submitted to quality control analysis using the Z´-factor, the 
equation is shown in Figure 3.2. The Z′-factor is a screening window coefficient. It describes 
how well separated the positive and negative controls are, and indicates the likelihood of false 
𝐶𝑒𝑙𝑙 𝑅𝑎𝑡𝑖𝑜 =
𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 (𝑆)
𝑚𝑒𝑎𝑛 𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟( 𝑁𝐶 )
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positives or negatives (Zhang et al. 1999). A good assay has a large signal window or separation 
band (>3-fold) and clear separation between the tails of the distributions of the controls. Values 
between 0.5 and 1(large separation band) are excellent, values between 0 and 0.5 (small 
separation band) may be acceptable, and values less than 0 (no separation band – variation 
bands overlap) indicate the assay is unlikely to be usable in a high-throughput context. 
Individual assay plate Z’-factors were derived from the negative controls (infected cells threated 
with 0.5% DMSO) and positive controls (non-infected cells). An experimental run was 
considered successful only if the plates Z’-factors were >0.5. 
 
Figure 3.2 Z’-factor determination. Histogram representing controls infection 
distribution. X-axis shows infection bins (%) and y-axis shows the frequency (%) 
of compounds per bin. The solid line represents the mean value. The dashed lines 
represent 3 standard deviations above and below the means. 
 Resazurin assay 
In order to evaluate the THP-1 cells viability at 34 °C and 37 °C, different THP-1 
cell densities (2000, 4000, 6000, 8000 cells/well) were plated into 384-well plates and incubated 
at 37 °C/5 % CO2 for 48 h. After this time, one plate was maintained at 37 °C and the other one 
was transferred to a 34 °C in a 5 % CO2 humidified incubator. At 84 h post cell plating, resazurin 
(Sigma R7017) was added to the plates at a final concentration of 10 µM and incubated for 
further 12 h. Then, plates were fixed and stained with Draq5 (BioStatus). Wells containing only 
media and resazurin were used as background control. 
 Determination of the drug exposure window 
On day 1, THP-1 cells were plated in 384 well plates at 7,000 cells/well in 25 μL 
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of RMPI complete media containing 50 ng/mL PMA, and incubated at 37 °C/5 % CO2 for 48h 
to complete differentiation. On day 3, promastigotes were added to the plate at 50 parasites/cell 
in 25 μL of RPMI media per well and transferred to a 34 °C/ 5 % CO2. On day 4, amphotericin 
B was serially diluted in 2-fold serial dilution in DMSO in 10 points in a polypropylene (PP) 
384 well plate using a 16-channel manual pipette equipped with disposable tips, followed by a 
dilution of 16.6-fold in PBS (“intermediate dilution”). Then, 10 μL of intermediate plate content 
were transferred onto plates containing Leishmania-infected THP-1. The starting test 
concentration was 25 μM. Each concentration was tested in triplets in the same plate. The plates 
were incubated at 34 °C/5 % CO2. Finally, plates fixed with 4 % paraformaldeh (PFA) at some 
time-point after experimental treatments (0, 24, 48, 72, 96 and 120h) and then subsequently 
washed, labeled and read in HCS instrument. 
 EdU incorporation test 
In order to evaluate the EdU incorporation in cells infected with L. amazonensis, 
EdU (Click-iT® Plus Alexa Fluor® 488 kit, Life Technologies) was added in the assay plates 
at 100 µM for 24 hours. Plates were fixed with 4% PFA for 15 minutes and permeabilized with 
0,5 % Triton X-100 in PBS for 20 minutes. Posteriorly, cultures were washed twice with 3% 
BSA and treated with Click-iT® reaction cocktail for 30 minutes, at room temperature, 
protected from light. For nuclear staining, cultures were incubated with with 5 μM Draq5 in 
PBS. Then plates were read in HCS instrument. 
 Tanimoto structural similarity index 
In order to identify common scaffolds, the Tanimoto structural similarity index 
was calculated using the online service ChemMine Tools (http://chemmine.ucr.edu/). 
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4 Results and Discussion 
There are two key points to be considered in a High Content Screening (HCS) 
assay: (i) the biologic model relevance and (ii) the imaging analysis. Although both aspects 
were developed concomitantly, in order to facilitate the understanding, this thesis approach 
them separately. Initially, it is described how two different commercial HCS systems were 
successfully used to generate quantitative data (section 4.1). Then, the establishment of the 
intracellular amastigote assay for dermotropic species is reported (section 4.2). The HCS assay 
for dermotropic species was validated by activity evaluating of a commercial library and widely 
used reference drugs, amphotericin B and miltefosine (section 4.3). The validation for 
viscerotropic species has been reported in the PhD thesis of Alcântara (Alcântara 2017). The 
section 4.4 gives an overview of the multi-species high content assay protocol. The sections 4.5 
and 4.6 report the screening of two libraries: LOPAC and Pathogen Box, respectively. Finally, 
section 4.7 indicates pan-antileishmanial compounds. 
 Image analysis protocol 
The HCS platforms are complex instruments with lots of components: the stage; 
the light source; the autofocus system; and the light path, including objectives, filters, mirrors, 
and the camera or photomultiplier tube. Firstly, and most important, is to use a calibrated 
equipment that always captures the same quality image, allowing to compare and reproduce 
data over time, for example, plate-to-plate and day-to- day. After the system is set up to acquire 
the best images possible, the next step is the optimization of image analysis parameters. The 
analysis software assign pixels to objects and characterize its features (intensity, color, size, 
shape, texture, or dynamics). Then, image analysis algorithms derive qualitative and 
quantitative measures of the features (Trask and Johnston 2015). 
In the protocol here described, the goal is to count the number of cells and classify 
the ones containing intracellular amastigotes, a measurement named as infection ratio. So, two 
objects are identified based on its features: cell and parasite. The object “cell” has two 
subregions: nucleus and cytoplasm. Using Draq5, a far-red fluorescent DNA stain, both 
parasites and host cells are detected. Though Draq5 is a stain specific for DNA, its background 
on cell organelles is enough for cytoplasm delimitation. As plates can be read using a single 
channel for fluorescence, there is a reduction of time in both image acquisition and analysis, 
representing an advantage considering large scale screenings. 
Fluorescence images were acquired using the Operetta system (Perkin Elmer). The 
objective has impact on performance and throughput, affecting the resolution, field of view, 
47 
detection sensitivity, and algorithm performance. Because resolution and field of view are 
inversely related, higher resolution results in a smaller field of view with fewer cells per image, 
requiring longer scan times to analyze acceptable number of cells. The 20x magnification was 
enough to identify cell and parasites. Higher magnifications would facilitate parasites detection, 
but it would also evidence artifacts. For Operetta 20x objective, the 384-well microplate can be 
subdivided into 35 imaging fields (each image with approximately 0.35 mm2). The lowest 
number of images that statistically represented the whole well was 4 (~1,000 cells), therefore 4 
images were acquired for each well. This correlation is only true if the distribution is 
homogenous throughout the well. Others acquisition parameters were also set up, such as: 
exposure time, focus and plate map. As the autofocus was not available in the device options, 
a multiple stacks imaging was performed, adjusting the focus to evidence the amastigotes. 
Harmony high-content analysis software is a commercial software designed for 
Operetta, Operetta CLS and Opera Phenix high-content screening systems. Figure 4.1 shows a 
raw image followed by analysis segmentation. Each specific parameter is adjusted empirically 
by trial and error from among available options. 
The single plan image analysis consists on the following sequential building block 
setups: 
• Raw image (Figure 4.1 A): represents the pseudocolored original image acquired by 
Operetta at 20x magnification. Parameters such as exposition, excitation and focus 
stacking were determined at the acquisition time in order to provide high quality images. 
• Find nuclei (Figure 4.1 B): responsible for detecting nuclei in the image. The detection 
is based on the highest nucleus intensity compared to its surrounding.  
• Find cytoplasm (Figure 4.1 C): delimits the cytoplasm; especially based on nuclei/cell 
areas and minimal contrast/intensity threshold. Some multinucleated cells are splitted in 
more than one individual cell. 
• Select population I (Figure 4.1 D): creates a subpopulation from the Find Nuclei 
population. This first “selection population” is applied in order to exclude cells that are 
not completely inserted in the image field. 
• Find spots (Figure 4.1 E): identifies individual intense spots (parasites) inside the host 
cells. The spots detection in based on the strong signal from the labeled DNA of the 
parasite nucleus and kinetoplast (indistinguishable under this magnification), within the 
limits of the previously defined cytoplasm area. The selected script allows, after fine 
adjustments, to detect the individual spots without generating, however, an excessive 
48 
number of false positives (in this case commonly generated by natural differences in 
cytoplasmic contrast or presence of cellular debris). 
• Select population II (Figure 4.1 F): selects infected cells from the whole population. 
The use of method “filter by properties” is adapted to consider as infected cells the ones 
presenting number of spots ≥ 1.  
 
Figure 4.1 Harmony software image analysis building-blocks. Images of THP-1 cells infected with 
L. braziliensis. A) Pseudocolored raw image acquired from Operetta microscope with a 20x objective. 
B) Nuclei detection. C) Definition of the cytoplasmic region. D) Elimination of cells that are not 
completely inserted in the image field (red cells). E) Spot detection (parasites). F) Infected cells are 
highlighted in green, noninfected cells are in red. Scale bar: 100 µm. 
After being configured, the whole script is tested on the positive and negative 
49 
controls in order to evaluate the detection of false positives false positives (non-infected cells 
are selected as infected cells due to cellular structures recognition as parasites by the software) 
and false negatives (infected cells are selected as a non-infected cells due to intracellular 
amastigotes that are not detected as a spot). For the infection ratio of non-infected cells, a 
maximum of 10% false positive was tolerated. The specific readouts chosen were: total host 
cells number, infected cells number, infection ratio and the number of parasites per each well. 
The software sensitivity was evaluated by using different cell densities and different 
infections ratios. THP-1 cells were plated at 2000, 3000, 4000, 5000, 6000 and 7000 cells/well 
densities. The density of 7000 cells/well was infected with various multiplicities of infection 
(MOIs) _ 10, 20, 30, 40 and 50. The defined scripts were able to successfully measure the 
number of cells. Detection of cells increases as the number of seeded cells rises, which 
demonstrate a linear correlation (Figure 4.2 A). A linear increment was also observed in 
infection percentage and ratio of spots/cell when cells were infected with different MOIs, 
hereby validating the sensitivity of the system (Figure 4.2 B and C). As consequence of using 
a single channel for both cell and parasite delimitation, cellular debris and other non-specifically 
stained artifacts on cytoplasm lead to false positive detection of parasites. Therefore, the 
software sensitivity is reduced to prevent high ratios of false-positive. The reduction in 
sensitivity contributes to non-identification of some true parasites as spots, as can be seen in 
Figure 4.1 E. In addition, the parasites features used to identify spots (size, contrast, intensity 
threshold and the minimal distance between two spots to consider two independent objects) are 
heterogeneous, mainly because the images are acquired in a single plan and amastigotes present 
a tridimensional disposition in the parasitophorous vacuole. The discrepancy between the real 
number of infected cells and the software analysis is corrected by normalization of data with 
positive and negative controls (as described in material and methods, section 3.12), thus 
calculating the infection inhibition percentage (named normalized activity). When the infection 
ratio of a sample well is higher than the mean value of negative control, the compound 
normalized activity will be negative, indicating an increase in the infection ratio. In the same 
way, but less obvious, when the infection ratio of a sample well is lower than the mean value 
of the positive control, the compound normalized activity will be greater than 100%. A sample 
can have an infection ratio lower than the non-infected cells. It occurs when the compound 
eliminates the parasites and, somehow, also decrease the incidence of debris and artifacts that 
mislead the detection of spots. 
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Figure 4.2 Harmony software sensitivity. THP-1 cells were seeded at different densities (2000, 3000, 
4000, 5000, 6000 and 7000 cells/well). A) The number of cells in the 4 images was counted by the 
software for different seeding densities/well. Next, the 7,000 cells/well density was infected with 
multiples MOI of L. braziliensis. B) Infection percentage and C) spots per infected cell was measured 
by the software for different MOIs. Data points are means and error bars represent the standard deviation 
of 16 wells. The straight lines are linear regression lines, R-squared values above. 
Some of the experiments here described used IN Cell Analyzer 2200 (General 
Electric) to acquire and analyze images instead of Operetta (Perkin Elmer). Each HCS 
instrument company has unique image analysis software. Image analysis algorithms from 
different sources may result in different EC50 values, even from the same image set. So, in order 
to check system-to-system variability, images of the same plates were acquired in the two 
equipment (Table 4.1). Then images were analyzed by Harmony software (Perkin Elmer) or 
Investigator software (General Electric). The Investigator software has a different interface and 
algorithm, but the steps of analysis are similar to those used in Harmony. Both image analysis 
softwares are intuitive and easy to navigate.  
Table 4.1 Comparation between Operetta and IN Cell Analyzer analysis 
      Z’-Factor   aInfection %   bSpots/cell 
L. amazonensis 
Operetta  0.89  89.81 (± 1.14)  17.77 (± 1.03) 
IN Cell  0.81  87. 42 (± 1.61)  11.36 (± 1.04) 
        
L. braziliensis 
Operetta  0.74  77.11 (± 4.01)  12.86 (± 1.21) 
IN Cell  0.73  78.93 (± 2.63)  8.13 (± 0.86) 
        
L. donovani 
Operetta  0.89  93.12 (± 1.31)  12.97 (± 0.76) 
IN Cell  0.78  86.78 (± 2.14)  7.41 (± 0.86) 
        
Non-infected 
Operetta  -  10.41 (± 1.69)  1.43 (± 0.14) 
IN Cell   -   14.33 (± 3.09)   0.21 (± 0.05) 
a Means (± Standard Deviation). 
b Means (± Standard Deviation) of spots per infected cell. 
 
As evident in Table 4.1, there was no statistical difference in the percentage of 
infected cells detected using Operetta or IN Cell Analyzer. The Z’-factor were high for both 
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systems. Even though the spots/cell number differ, this is not the parameter used to evaluate 
compounds activity. Besides, as already mentioned, the determination of parasites (spots) is not 
absolute but proportional to the parasite load. 
The most important aspect to be compared is compounds activity. Thus, the dose-
response curve of two reference compounds for three species were assessed by Operetta and IN 
Cell Analyzer using the same assay plates to acquire and analyze images. As can be seen in 
Figure 4.3, the two generated curves are noticeably overlapping for all tested conditions. The 
data similarity is reinforced by the non-significant difference between pEC50 values (Table 
4.2). 
 
Figure 4.3 DRCs of reference compounds assessed by Operetta and IN Cell Analyzer. THP-1 cells 
were infected with L. amazonensis, L. braziliensis or L. donovani and treated with amphotericin b or 
VL-2098. The X-axis indicates the log of compounds concentration (molar) and Y-axis indicates the 
normalized antiparasitic activity, which represents the inhibition of infection in relation to controls. Data 
points are means and error bars represent standard deviations of triplicates. 
Table 4.2 pEC50 values determined by Operetta and IN Cell Analyzer analysis 
  L. amazonensis  L. braziliensis  L. donovani 
 
Operetta IN Cell  Operetta IN Cell  Operetta IN Cell 
AMB 4.81 4.75  5.01 4.98  5.02 5.11 
VL-2098 4.56 4.65  4.93 4.93  3.40 3.49 
pEC50 = -log EC50 (M) 
Commercial image analysis softwares are developed to be used in a variety of 
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assays. However, their development is based on limited number of cell lines, staining reagents, 
phenotypic changes, for which specific image analysis algorithms were developed to analyze a 
particular set of features and then extrapolated to similar assays. So, the difficulty for a precise 
recognition of a particular cellular phenotype is not surprising. Despite that, it is possible to 
configurate the script in order to improve accuracy. Certainly, some platforms provide more 
configuration flexibility by the user than others. The ideal would be to configurate a specific 
algorithm for each assay, increasing sensitivity and specificity. The development of in house 
software is an option, but it is time and resource consuming, besides, it requires high technical 
expertise.  
Although the exact number of parasites per cell was not detected by neither of the 
commercial softwares here used, the event of interest, that is infection ratio reduction, was 
satisfactory assessed by both platforms. It should, however, be mentioned that precise number 
of parasites per cell would be crucial to evaluate the replicative dynamic of intracellular 
amastigotes. In that case, a second stain specific for amastigotes would be enough to achieve 
accuracy. Which is recommended for small sets of compounds, as in secondary assays or 
mechanism of action studies. However, in the case of primary screening, a second channel for 
fluorescence virtually doubles the time of image acquisition and analysis. Also, the higher 
number of images requires more storage space. Proper data storage and management is one of 
HCS challenges. It is highly recommended to keep backups of all images. 
 Establishment of the intracellular Leishmania spp. assay for dermotropic species 
A range of tegumentary manifestations occurs due to Leishmania spp. infection. 
The most important determinant in the clinical outcome is the parasite species. Here the 
establishment of an intracellular assay is described for three species: L. amazonensis, L. 
braziliensis and L. major. When infected with L. amazonensis, patients often develop the severe 
syndrome termed diffuse cutaneous leishmaniasis. L. braziliensis is the species most often 
associated with the highly disfiguring mucocutaneous leishmaniasis. Despite L. major is most 
related to localized self-healing cutaneous leishmaniasis, its epidemiological importance is well 
known. 
For drug discovery purpose, choosing the host cell is a decisive step in the 
establishment of an intracellular assay, as antileishmanial activity of compounds can be 
dependent of the host cell (Seifert et al. 2010). Beyond that, others aspects are also relevant in 
HCS assays context. The continuously requirement of large quantities of cell represents a 
bottleneck for the use of primary cells. Cell lines provide high densities of homogeneous 
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populations, an attractive for high-throughput assays, and no animals are involved, which is 
ethically attractive. Also, some morphological features are desired for image analysis: a 
monolayer growth, enabling proper cells individualization, and large cytoplasm, so amastigotes 
can be easily identified. To select the cell host, three cell lines were examined: Raw 264.7 and 
J774A.1 from murine origin, and THP-1 of human origin. 
The RAW 264.7 and J774A.1 cell lines have a very small cytoplasm, what is 
problematic to spots identification. Furthermore, even after extensively effort to de-clumping 
before plating, both cell lines display multilayer points before achieving confluence regardless 
initial density, as indicated in Figure 4.4. At the end, no further attempts were performed to 
overcome such difficulties and these cell lines were not further considered for assay 
development. 
 
Figure 4.4 Standardization of RAW 264.7 and J774A.1 cell lines density in 384-well plates. Cells 
were plated at three different densities: 2000, 4000 and 80000 cells/well. After 96 hours, the plates were 
fixed and stained. Images were acquired by Operetta High Content System (Perkim Elmer). Arrows 
indicates cell clusters. Scale bar: 100 µm. 
Regarding THP-1, in order to determine the cell seeding density to achieve 
confluence, different cell densities were plated into 384-well plates in presence of 50 ng/mL 
PMA (data reported in Alcântara, 2017). The density of 4,000 cells/well did not reach complete 
confluence. The formation of cell clusters at the density of 10,000 cells/well impaired the cells 
individualization by the analysis software. The density of 7,000 cells/well provided an optimum 
confluence. Hence, 7,000 cells/well was the established density for 384-well plates (see figure 
in Appendix 1). 
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The phenotype of PMA-differentiated THP-1 macrophages is dose and time 
dependent, thus several protocols has been reported (Starr et al. 2018). Their phagocytic 
capacity is a central function for Leishmania spp. infection assay. To measure differentiated 
THP-1 phagocytosis, cells were exposed to 50 ng/mL PMA for 24h, 48 h or 72h, followed by 
1 h incubation with fluorescent zymosan particles, and subsequent washing with PBS to remove 
non-internalized particles. These zymosan particles are trypsin-treated cell wall preparation of 
Saccharomyces cerevisiae. Their phagocytosis is mediated by a repertoire of different receptors 
that recognize the different components of the particle and mediate internalization (Underhill 
2003). Figure 4.5 shows the results. After 48h of differentiation a reasonable number of 
particles were phagocyted. Although the phagocytic capacity peaked at 72h-differentiation 
induces highest phagocytic capacity, 48h was chosen for the regular assay. This is because the 
longer the assay window, the greater the chances of variability due to external interferences. It 
is worth pointing out that cell differentiation is the first of a series of sequential steps, therefore, 
48 h is not the assay total period. 
 
Figure 4.5 Evaluation of THP-1 cells fagocytic capacity after PMA differentiation. Cells were 
activated with 50ng/ml PMA for 24, 48 or 72h, and then incubated with 25, 50 or 100 fluorescent 
zymosan particles/cell for 1h. A) Psedocolored image of 48h-diferentiated cells incubated with 25 
particles/cell (green). Nuclear staining with Draq5 (red). Scale bar: 25 µm. B) The number of phagocited 
particles for each zymosan density incubation (25, 50 or 100) were mesured by Harmony software. Bars 
are means and error bars represent the standard deviations from one experiment. 
Stimulation with PMA for 48 h was sufficient for differentiation of THP-1 into 
macrophage-like cells, as demonstrated by cell adherence, cytoplasmatic area enlargement and 
phagocytic capacity. A washing step after differentiation process has been reported by other 
researchers in order to remove PMA and avoid unexpected interferences (Duffy et al. 2017; 
Jain et al. 2012; De Muylder et al. 2011). Thereby, the effect of removing PMA after 48h of 
differentiation was investigated (data reported in Alcântara, 2017). Cultures in which PMA had 
been washed off were more similar to undifferentiated monocytes, as evidenced by lower cell 
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adherence, smaller cytoplasmatic area and increase in population growth rate (see figure in 
Appendix 1). Accordingly, maintenance of PMA in the culture medium throughout the duration 
of the biological assay ensured morphologically macrophages-like cells. 
It is well known that Leishmania spp. present different temperature tolerances for 
intracellular growth (Berman and Neva 1981; Sacks et al. 1983). This thermosensitive influence 
the parasite localization in the human host, as skin temperature is lower than internal 
temperature. In order to confirm the best temperature for cutaneous species infection, 
experiments were conducted at two temperatures: 34 and 37 °C. The THP-1 cells were 
differentiated in two 384-well plates at 37°C for 48h. Next, cells were infected with late-
stationary phase promastigotes of L. amazonensis, L. braziliensis or L. major at different 
multiplicities of infection (MOIs) _ 10, 20 or 40. Immediately, one plate was incubated at 34 
°C and the other at 37°C for further 96h. Figure 4.6 shows representative images from both 
conditions. 
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Figure 4.6 Infection performed at 34°C is better for CL species. Representative images of THP-1 
cells infection with L. amazonensis, L. braziliensis and L. major at 34 or 37°C after 96 h of infection. 
Raw images acquired with Operetta. Scale bar: 50 µm.   
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As can be seen in Figure 4.7, clearly, incubation at 34°C resulted in increased 
infection ratios as well as increased numbers of intracellular amastigotes when compared with 
results at 37°C. L. braziliensis was the most thermosensitive species, intracellular amastigotes 
were completely eliminated after 96 hours incubation at 37°C. 
 
Figure 4.7 Infection performed at 34°C increases CL species infectivity. A) Infection Ratio of THP-
1 cells infected with different MOIs of L. amazonensis, L. braziliensis and L. major at 34 or 37°C (96 h 
of infection). B) Spots/cell of THP-1 cells infected with different MOIs of L. amazonensis, L. 
braziliensis and L. major at 34 or 37°C (96 h of infection). Bars are means and error bars represent the 
standard errors. Three independent experiments were performed. 
Mammalian cells are usually cultured at 37°C in the incubator supplied with 5% 
CO2 unless specific research purpose is required. Thus, the THP-1 cells viability was 
investigated in both temperatures. The viability analysis following incubation at 34 or 37 °C 
was performed by a resazurin assay, as described in material and methods section 3.13. The 
number of cells was also evaluated using the Harmony software analysis in order to prove there 
was the same number of cells in both plates. There was no difference in the cell counts or cell 
viability between the two conditions (Figure 4.8 A and B). Nevertheless, the cells presented 
slightly smaller nucleus and cytoplasm areas at 34 °C (Figure 4.8 C). This morphological 
change is expected, since cell metabolism decreases at lower temperatures, and metabolism 
affects cell size (Miettinen and Björklund 2017).  
In accordance with previous reports, 34° C was established as the temperature to 
infect THP-1 cells with dermotropic species of Leishmania. 
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Figure 4.8 THP-1 cells incubated at 34 °are viable. A) Fluorescence (560/590nm) signal after 12-
hour incubation of THP-1 cells with resazurin at 34 and 37°C. It shows a linear correlation between 
fluorescence and cell number. B) Total number of cells in 7 fields of the well at 34 and 37°C. It shows 
a linear correlation between seeding cell number and the software analysis. C) Nucleus Area and 
Cytoplasm Area of THP-1 cells plated at 34 and 37°C. Squares and bars are means and error bars 
represent the standard errors. Three independent experiments were performed. *p < 0.05, t-test. 
Several culture media are currently used for maintenance of Leishmania spp. 
promastigotes, which are determinants for culture viability and parasite infectivity (Castelli et 
al. 2014; Childs et al. 1978; Merlen et al. 1999). More specifically, studies by Santarem et al. 
showed that parasites cultured in distinct culture media may exhibit changes in metacyclic gene 
expression, resulting in different levels of infectivity in vitro and in vivo (Santarém et al. 2014). 
Considering this, different promastigote culturing media (LIT, RPMI, M199, Grace’s and 
Schneider’s) were tested and compared in terms of promastigote growth curve and infection 
profile. Starting from the same original stock, L. amazonensis, L. braziliensis and L. major 
promastigotes were cultured for 8 passages in the different media to ensure that parasites were 
fully adapted to the individual culture media composition, and only then their growth curves 
and infectivity were evaluated. The results are summarized in Figure 4.9. Only M199 and LIT 
media were able to support growth of all three species. 
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Figure 4.9 Evaluation of growth and infectivity of promastigotes cultured in different media. A) 
Growth curves of L. braziliensis, L. amazonensis and L. major in different insect cell culture media. B) 
Infection ratios of THP-1 cells infected with L. braziliensis, L. amazonensis and L. major cultivated in 
different media (MOI 20) after 120 h of infection. Bars are means and error bars represent the standard 
errors of two independent experiments. 
The promastigotes entered stationary phase around day 6 in all media; from seven 
days onward, the parasites viability decreased (observed by visual inspection), so 6-day old 
promastigote culture was chosen for test the infection in THP-1. It was previously reported, that 
stationary phase promastigote culture results in higher infection ratios because of the 
enrichment of metacyclic promastigotes in the culture media (da Luz et al. 2009). Promastigotes 
cultured in M199 achieved higher infection ratios, followed by those cultured in LIT (Figure 
4.9 B). Therefore, M199 was chosen as the culture media for all species.  
In order to confirm 6-days as the best period of promastigotes culture before 
infection, 5-day, 6-day and 7-day old parasites were used to infect THP-1 cells at a MOI 20. 
The infection ratios were evaluated at 96 h post-infection (see Figure 4.10 A). Only L. major 
proved to be more infective with a 5-day old culture, instead of 6-day and 7-day old ones. For 
L. braziliensis and L. amazonensis there was no significative difference. 
As all the standardization experiments were performed using 25 cm2 (T25) flasks 
to culture promastigotes, a test with different flask sizes (T25, T75 and T175) was performed 
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to determine whether promastigote culture scaling up would affect metacyclogenesis and, 
consequently, the infection ratios. No relevant impact on infection ratio was observed, showing 
that any size of flasks could be used to culture the parasites (Figure 4.10 B). 
 
Figure 4.10 Infection parameters standardization. A) Infection ratio and spots/cell of infected 
THP-1 cells with day-5, 6 or 7 Leishmania spp promatigotes (MOI 20), 96h after infection. C) 
Infection ratio and spots/cell of infected THP-1 cells with day-6 promastigotes cultured in different 
flask sizes (25, 75 and 175 cm2), 96 h after infection. Bars are means and error bars represent the 
standard errors of two independent experiments. *p < 0.05, t-test. 
As a mean to choose the assay multiplicity of infection (MOI), infection ratio 
dynamic was evaluated. Figure 4.11 shows results for L. braziliensis. There was a linear 
increment in infection ratio correlated with the MOI, reaching saturation at MOI 50 (Figure 
4.11 A). This correlation is sustained over time. The number of spots/cell was also proportional 
to the MOI up to MOI 50 (Figure 4.11B). Both infection ratio and spots/cell slightly increased 
after 8 days of infection. But at the same time there was an accentuated decrease of the cell 
number (Figure 4.11 C). The infected cells tend to have a better survival than the non-infected 
ones, which may explain the apparent increase in the infection ratio. Interestingly, cytoplasm 
area enlargement stabilized only after 8 days of infection, which may be related to complete 
THP-1 differentiation process (Figure 4.11D). Similar results were obtained for L. amazonensis 
and L. major (Data not shown).  
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Figure 4.11 L. braziliensis infection ratio dynamic over time. A) Infection Ratio. B) Mean number of 
parasites/cell. C) Mean cell number of THP-1 cells. D) Mean Cyptoplasm Area of THP-1 cells. Dots 
are means and error bars represent the standard deviations of one experiment. 
The plateau of infection ratio and intracellular amastigotes at high MOIs is 
expected, since macrophages have a limited uptake capacity. The MOI 50 was enough to 
achieve the highest infection possible for all species under the assay conditions. Thus MOI 50 
was chosen for further experiments. The standardization of different MOIs for each model 
aiming to get more physiologically representative rates would be extremely laborious, and 
probably would lead to great differences in infection ratio and number of intracellular 
amastigotes among species.  
The assay treatment window was determined by evaluating the time needed for 
reference compounds (amphotericin B, miltefosine or pentamidine) reaching maximum effect 
under these in vitro experimental conditions. Infected macrophages were exposed to nine 
different concentrations of serially diluted drugs. Copies of identical plates were prepared to 
allow determination of infection ratio each 24 hours up to 192h of treatment exposure. A 
representative panel of images from infected cells is shown in Figure 4.12. 
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Figure 4.12 Representative images panel of THP-1 cells infected with Leishmania spp. 
Pseudocolored raw images acquired with Operetta microscope (20x objective). The images are from 
the 0.5% DMSO control of each specific time point after infection. Scale bar: 50 µm. 
The cidal dynamics (‘time-kill’) plot for each drug is presented in Figure 4.13 and 
pEC50 values are in Table 4.3. The data show both concentration and time-dependent activity 
for amphotericin B and miltefosine. Amphotericin B was the drug with broader activity 
spectrum. Miltefosine was most active against L. braziliensis and only partially active against 
L. amazonensis. Apparently, L. major showed resistence to all tested drugs. At least 96 h were 
necessary to fully achieve the elimination of L. amazonensis amastigotes under amphotericin B 
exposure. Although the plot for L. braziliensis shows a borderline infection ratio at 96h due to 
software detection limitation (spots false-positive detection), amphotericin B completely 
eliminated parasite infection, as inferred by visual images inspection. Thus, for L. amazonensis 
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and L. brazilienis, based on amphotericin results, 96 hours was defined as drug exposure 
window to detect unambiguous activity/efficacy for compounds under these conditions. Also, 
the minimal-effective concentration of 10 µM was determined as a positive control. The lack 
of activity for pentamidine is not surprising, since it is reported that this drug only reduces the 
number of intracellular amastigotes but not the number of infected cells, and here infection ratio 
is the parameter evaluated (Wang et al. 2010). 
 
Figure 4.13 Determination of the drug exposure window. THP-1 cells were infected with L. 
amazonensi, L. braziliensis and L. major (MOI 50) for 24 h prior to addition of compound (previously 
serially diluted by the factor of 2-fold, as indicated the by the colors legend). Activity was analyzed 
every 24 h, starting right after compound addition (time point 0 h), up to 192 h. Data points are means 
and error bars represent standard errors of two independent experiments. 
  
64 
Table 4.3 pEC50 values at 72-, 96-, and 144-h of continuous reference compounds exposure 
 Amphotericin B  Miltefosine  Pentamidine 
 72h 96h 144h  72h 96h 144h  72h 96h 144h 
L. amazonensis 5.78 6.08 6.06  - 4.65 4.76  - - - 
L. braziliensis 6.20 6.26 6.40  - 5.01 5.74  - - - 
L. major - 5.77 6.08  - - -  - - - 
Data refer to pEC50 mean from two independent experiments. pEC50 = -log EC50 (M) 
The time- and concentration-dependent activity of the compounds are in line with 
recently reported data. Maes and collaborators demonstrated that more than 240 h are required 
for miltefosine (10 mM) and amphotericin B (2 mM) to completely eliminate all viable 
amastigotes. Their protocol used L. donovani and L. infantum spleen-derived amastigotes to 
infect primary peritoneal mouse macrophages, and cydal dynamics was assessed by the 
quantification of recovered amastigotes differentiated to promastigotes (Maes et al. 2017). In 
another work, Voak et al. reported infection of bone marrow derived macrophages with L. 
donovani amastigotes freshly harvested from the spleen, and subsequent evaluation of infected 
cells percentage for different amphotericin B and miltefosine concentrations along with 
measurement of cellular drug accumulation. The time to reach 50% of maximum drug 
penetration (t50) was 55.72 h for amphotericin B and 100.01 h for miltefosine. Highlighting 
that at 10 µM miltefosine, the timepoint of maximum total cellular drug concentrations 
preceded the timepoint at which maximum parasite killing was observed (Voak et al. 2018). 
The apparent resistance of L. major might be related to its high multiplication rate 
even at 34 °C (Eren et al. 2018). So, the growth curve of parasites with or without PMA was 
assessed. The initial density was comparable to parasite density used to infect cells at MOI 50. 
As can be inferred by Figure 4.14, PMA presented no effect on growth curve of all species. L. 
major keep multiplying at 34 °C during the incubation period. As there is no washing step to 
remove non-internalized parasites in the protocol here reported, the remain extracellular 
promastigotes can multiply and re-infect neighboring cells, misleading the compounds activity 
measurement. No further investigation was conducted. At the end, it was decided afterwards to 
not continue experiments with L. major, given that promastigotes multiplication at 34 °C might 
interfere with compounds activity. 
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Figure 4.14 Growth curve of promastigotes at 34° C. The initial density of 1.5x107 
parasites/mL is comparable to parasite density used to infect cells at MOI 50. Data points are 
means and error bars represent standard errors of two independent experiments 
The attempts to remove non-internalized promastigotes by washing the microplates 
resulted in high rates of cell detachment, which drastically elevated variability in cell number 
among wells replicates, thus impairing the use of cell ratio data, an essential parameter in HCS 
approach (data not shown). Lastly, by not adding a washing step, the reliability on the cell 
viability prediction was assured. 
L. amazonensis is well known by its large parasitophorous vacuoles hosting several 
amastigotes, a strategy to subvert host cell defenses, providing an environment with lower 
activities and/or concentrations of hydrolytic enzymes vacuoles (Real and Mortara 2012). The 
biogenesis mechanisms behind the formation of these communal vacuoles in not totally 
elucidated. As such feature could not easily be seen in the assay images, and representative 
images of L. amazonensis infecting THP-1 was not found in the literature, it was questioned if 
THP-1 cells were able to generate such large vacuoles or if the high MOIs impaired to observe 
them. So, differentiated THP-1 cells were infected with one parasite per cell ratio in T25 flasks, 
and incubated until observation of vacuoles could be done under the microscope. After 13 days, 
infected cells were harvested and plated in 384-well plates for 24h. At this time point, treatment 
with amphotericin was added for 96h. In the last 24 h of the experiment, EdU reagent was added 
to some wells, as described in material and methods section 3.15. Typical L. amazonensis 
vacuoles were successfully observed in THP-1 cells (Figure 4.15 A). Also, EdU incorporation 
in 31.27% of parasites after 17 days of infection indicate an active process of replication. 
Amphotericin B activity was noticeable the same when compared with the conventional assay 
(infection with MOI 50 for 24h directly on 384-well plate) concomitantly performed  (Figure 
4.15 B). 
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Figure 4.15 L. amazonensis communal parasitophorous vacuoles in infected THP-1 cells. A) 
Representative images of THP-1 cells after 17 days of infection. Pseudocolored raw images acquired 
with Operetta microscope (20x objective). Scale bar: 25 µm B) Amphotericin B dose response curve 
for MOI 1 (blue) and conventional protocol _MOI 50 (red). Data from one experiment. 
Albeit THP-1 cell line is currently used as the host cell in the majority of 
Leishmania HCS assays, their use is not without concerns. THP-1 cells differ from primary 
macrophages in the phagocytic activity, the cytokines production and the regulation of the 
oxidative burst. Ideally, primary macrophages of human origin would be preferable. However, 
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it is difficult to obtain a reliable and homogeneous supply of human primary cells at a scale 
suitable for routine screening. An alternative is to use murine primary mouse macrophages. In 
order to investigate the impact of the host cell on compounds selection against Leihsmania spp., 
an attempt of using bone marrow derived macrophage (BMDM) was done. Initially, the 
infection profile of L. amazonensis and L. braziliensis was evaluated. The differentiation of the 
BMDM was performed as described in the methodology, section 3.9. Primary macrophages 
were plated 24 hours prior to infection and THP-1 cells 48 hours prior. Stationary phase 
promastigotes were used to infect cells at different MOIs. The plates were fixed every 24h post-
infection.  
Both species were able to establish infection in both cell types. Representative 
images of the infection after 120 hours are shown in Figure 4.16.  
 
Figure 4.16 Representative images of infected THP-1 and BMDM cells. Pseudocolored raw 
images acquired with Operetta microscope (20x objective). Infection with L.amazonensis or L. 
braziliensis at MOI 20. Scale bar: 50 µm. 
Infected THP-1-derived macrophages inhibit Leishmania species growth but do not 
eliminate them, infection ratio and number of amastigotes were stable up to 120 hours. By 
contrast, primary macrophages derived from murine bone marrow were able to contain L. 
braziliensis, a significant decrease in the rate of infection in BMDM begins after 48h, almost 
completely eliminating all amastigotes at 120 h time point (Figure 4.17). The decrease in L. 
braziliensis BMDM infection data are in agreement with previous report (Novais et al. 2009). 
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L. amazonensis causes chronic infection in balb/c mouse, but in contrast the animals 
cure from infection by L. braziliensis. This death of L. braziliensis occurs by an interferon 
gamma-dependent mechanism (DaMata et al. 2015; DeKrey et al. 1998). Possibly, the results 
obtained in vitro reflect what occurs in vivo. 
Altogether, these results indicate THP-1 cells as a more robust model to assess 
activity against various species of Leishmania. 
 
Figure 4.17 Infection dynamic of L. amazonensis and L. braziliensis in THP-1 and 
BMDM cells. Data points are means and error bars represent standard errors of two 
independent experiments. 
 
 HCS assay validation for dermotropic species 
After careful standardization of biological models and image analysis, the next step 
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is the assay validation. The validation consists of experiments and subsequent data analysis to 
ensure that the assay is acceptable for its intended purpose, which in this case is reliability and 
robustness in compound activity detection. 
The dose-response curves (DRCs) of amphotericin B and miltefosine were assessed 
in ten independent experiments. Figure 4.18 shows a fairly consistent determination of pEC50 
values over time. 
 
Figure 4.18 Validation of potency determination. Box plots of ten independently determined pEC50 
values of amphotericin B and miltefosine for L. amazonensis and L. braziliensis. The plot shows 
median (line within box), 25th and 75th percentiles (box), and minimum and maximum (whiskers). 
Circles indicate outliers. 
To further characterize the assay reproductivity, the pEC50 of a small library 
composed by 30 compounds from collaborators were determined in two independent 
experiments. A Bland-Altman plot was used to evaluate the agreement between two 
experimental runs. In such cases, the use of correlation coefficients is misleading, because 
correlation quantifies the degree to which two variables are related. But a high correlation does 
not automatically imply that there is good agreement between the two data sets. The Bland-
Altman statistical method constructs limits of agreement based on the mean and the standard 
deviation. The resulting graph is a scatter plot XY, in which the difference of the two paired 
measurements is plotted against the mean of the two measurements (Bland and Altman 1986). 
A confidence interval of 95% is used to determine limits of agreement. 
The Bland-Altman plot (Figure 4.19) showed that the mean difference in pEC50 is 
0.01 for both species, which is very close to 0, so there is no significant variation from one 
experiment to the other. The limits of agreement, 0.14/-0.16 for L. amazonensis, and 0.21/-0.21 
for L. braziliensis are acceptable. Calculated MSD (minimum significant difference) of all the 
compounds tested were lower than the reported to most cell-based assays (0.4-0.5). The MSD 
indicates the largest potency difference that can be considered random (Murray 2013). Thus, in 
this assay, the required difference should be greater than 0.21 between two compounds pEC50 
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values to assure that the pEC50 for one compound is truly different to that of another compound. 
 
Figure 4.19 Determination of Minimum Significant Difference (MSD). Bland Altman plot of the 
log potency differences vs the mean data of two independent experiments. The continuous line is the 
mean difference between measurements, and doted lines represent the 95% confidence interval limits 
of agreement. MSD is defined as 2*SD of log potency differences. pEC50 = -log EC50 (M). 
The current protocol was also validated to single-point test by screening a 
commercial library of pharmaceutically active compounds (LOPAC). This biologically 
annotated collection of inhibitors, receptor ligands, and approved drugs impacts most signaling 
pathways and covers all major drug target classes. Highly pure compounds are widely used to 
validate screening assays because the reproducibility is better assessed. The library is composed 
by 1,280 compounds, which were distributed in 4 plates. Compounds activities were assessed 
twice in independent runs. 
For each screening run, three control plates were prepared: two plates of reference 
compounds dose-response curves, which allow to verify inter-plates activity variation during 
the assay. In addition, to evaluate the infection ratio consistence within the same plate, all wells 
of one plate were treated with 0.5 % DMSO (negative control). Because systematic bias that 
yields higher values in a pattern across a plate can mask the real differences between wells, thus 
hiding important information. All pipetting steps are always performed in the same sequence: 
(i) DRC1 plate, (ii) DMSO plate, (iii) compounds plates, and (iv) DRC2 plate. See plate maps 
on Figure 4.20. 
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Figure 4.20 Plate maps showing controls and samples positioning. As indicated in the legend, 
colours represent: 0.5% DMSO treated infected cells – negative control (red), non-infected 
cells (green), 10µM amphotericin B treated wells – positive control (light blue), samples 
(grey) and DRC amphotericin B (dark blue). ND = non determined. 
The criteria for approving a screening run was dependent on Z’-factor values (> 
0.5); coefficients of variance (< 20%); pharmacological validation as assessed by dose response 
curves for amphotericin B (EC50 value and maximum activity); and evaluation of any type of 
plate position effects such as edge effects, particularly important for assays with long incubation 
periods. The statistics data for both species are shown in TTable 4.4. 
Table 4.4 LOPAC screening for L. amazonensis and L. braziliensis 
 L. amazonensis L. braziliensis 
Z’-factor 0.65 ± 0.04 0.76 ± 0.07 
CV cell number (%) 5.2  4.7  
CV infection ratio (%) 11.74  11.38  
IR 0.5% DMSO 63.27 ± 6.17 69.83 ± 9.25 
IR Non-infected 10.15 ± 2.27 9.49 ± 2.19 
IR 10 µM AMB 15.03 ± 4.01 22.31 ± 8.86 
Coefficient of variation (CV) is relative to cell number and infection ratio from all 
wells of two 0.5% DMSO plates (one from each run). Z’-factor and IR data are 
Mean ± Standard Deviation from 12 plates (6 from each independent run). 
In summary, both species had a good window between the positive and negative 
controls and had a robust and reproducible performance between runs (Figure 4.21 A). The 
mean ± standard deviation of Z’-factor values of both runs was 0.65 ± 0.04 for L. amazonensis 
and 0.76 ± 0.07 for L. braziliensis, which give confidence in the reproducibility and the quality 
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of the assay (Figure 4.21 B). The Bland Altman plot shows that the mean difference of 
normalized activity for both species was very close to 0 and the limits of agreement are 
acceptable, considering a highly complex biological assay (Figure 4.21 C). 
 
Figure 4.21 Single point screening validation for L. amazonensis and L. brazililensis. A) 
Amphotericin B dose-response curves. B) Z-factor values. C) Bland Altman plot of the normalized 
activity differences vs the mean between the data of two runs. R1: run 1 and R2: run 2. The continuous 
line is the mean difference between measurements, and doted lines represent the 95% confidence 
interval limits of agreement. 
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Overall, the HCS assay here described was successfully validate for two cutaneous 
species of Leishmania. The validation for visceral species (L. donovani and L. infantum) has 
been reported in the PhD thesis of Alcantâra (Alcântara 2017). 
 The multi-species high content assay  
A multi-species high content assay was established and validated for some of the 
most clinically relevant Leishmania species: L. amazonensis, L. braziliensis. L. donovani and 
L. infantum. Figure 4.22 shows an overview of the HCS assay, a more detailed description can 
be found in the materials and methods (section 3.11). THP-1 differentiated macrophages are 
infected with stationary phase promastigotes in 384-well plates. After 24 hours of infection the 
cells are exposed to compounds. Plates are fixed after 96 hours of experimental treatments and 
then subsequently washed, labeled and read in an HCS instrument. The images are processed 
by a software analysis, providing specific readouts: total host cells number, infected cells 
number, infection ratio and the number of parasites per each well. Data are subsequently plotted 
in proper graphs in order to facilitate visualization. 
 
Figure 4.22 General scheme of Leishmania high content assay. A) Biological 
in vitro assay steps. B)  High content imaging workflow. 
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As mentioned before, the parasites features used by the analysis software to 
designate amastigotes as objects (spots) are heterogeneous. Leishmania species generated 
different infection profiles bringing forth morphological variations in the host cells, as staining 
differences for amastigotes (size, contrast, intensity threshold and distance between two spots). 
For instance, L. amazonensis nucleus/kinetoplast DNA is weakly stained by draq5, meaning the 
threshold between spots and cytoplasm background is low, which result in poor detection of 
intracellular amastigotes despite the high infection level, as observed by images inspection 
(Data not shown). Therefore, the software script parameters were optimized for each species in 
order to obtain an appropriate cell segmentation as well as the best parasite detection possible. 
Thus, ensuring a good separation between the controls and, consequently, good z’-factor. 
Nevertheless, comparison of data between species can be made only in terms of normalized 
activity. There is a bias in any conclusion based on comparison of the infection ratio or 
spots/cell number. Even so, the raw data of infection ratio and spots/cell are important to 
evaluate the assay variability. 
The differences in the pattern observed for Draq5 staining was not further 
investigated. The same protocol was used to dye all plates (volume, concentration and time of 
incubation) as well as the reading filter and exposure time. Probably, the multiplication ratio of 
each species plays a role in this matter, since Draq5 staining is stoichiometric and can be used 
for DNA content analysis in cell proliferation studies.  
The activity of amphotericin B and miltefosine was evaluated for the four species. 
Figure 4.23 shows the DRCs and Table 4.5 displays the pEC50 values. The amphotericin B 
activity was highly consistent to all species, reaching 100% of effectiveness and similar pEC50 
values (6.3 ± 0.1), while miltefosine showed variable interspecies efficacy (78-100%) and 
potency (6.0 ± 0.32). Variation in miltefosine sensitivity for both promastigote and amastigote 
stages has been extensively reported (revised in Croft et al. 2006). 
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Figure 4.23 Dose-response curves of reference compounds for Leishmania species. 
 
Table 4.5 pEC 50 values of reference compounds for Leishmania species. 
 L. amazonensis L. braziliensis L. donovani L. infantum 
Amphotericin B 6.2 6.4 6.3 6.2 
Miltefosine 5.7 5.8 6.1 6.4 
pEC50 = -log EC50 (M) 
The pEC50 values obtained for amphotericin B (6.3 ± 0.1) are quite in agreement 
with the mean data previous reported (6.8 ± 0.4, see Table 1.4). The variance in compounds 
potency is expected due to differences in the assay formats. Particularly, the variation in MOI, 
the distinction of cell host and the disparity in treatment exposure. More important than precise 
equivalence with others reports is the reproductivity of the data, which is shown in Figure 4.18. 
In order to evaluate the correlation of compound library screenings for different 
species, the results obtained for two distinct collections were analyzed. Although the principal 
motivation for screening of the LOPAC library was to validate the assay, this library contains 
FDA-approved drugs and pharmaceutically relevant compound structures, providing 
predictable activity profiles against a wide range of drug targets (kinases, proteases, GPCR's, 
etc.). The Pathogen Box (PBox) is an open-access collection provided by Medicines for Malaria 
Venture (MMV). It contains ~400 diverse, drug-like molecules previously reported as active 
against a range of different pathogens, predominantly Plasmodium, Mycobacterium, and 
kinetoplastid parasites (T. brucei, Leishmania spp., and T. cruzi).  
 Library of Pharmaceutically Active Compounds (LOPAC) 
This library was screened twice against L. amazonensis, L. braziliensis and L. 
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donovani intracellular amastigotes at 50 µM. Despite interspecies phenotypic variations, all 
models presented a good window between the positive/negative controls and had a robust and 
reproducible performance between runs (Table 4.6). 
Table 4.6 LOPAC primary screening quantitative data 
 L. amazonensis L. braziliensis L. donovani 
Z’-factor 0.65 ± 0.04 0.76 ± 0.07 0.77 ± 0.05 
IR 0.5% DMSO 63.27 ± 6.17 69.83 ± 9.25 76.55 ± 4.73 
IR Non-infected 10.15 ± 2.27 9.49 ± 2.19 7.02 ± 1.47 
IR 10 µM AMB 15.03 ± 4.01 22.31 ± 8.86 11.40 ± 2.30 
Z’-factor and IR data are Mean ± Standard Deviation from 12 plates (6 from each independent run). 
There are two common strategies to select the compounds from a primary screening 
that will be tested in confirmatory assays: determination of a cut-off score (e.g. 50% of activity) 
and taking compounds with activity values within three standard deviation of the positive 
controls. Due to variable sensivity among species, a cut-off of 50 % activity and 0.5 cell ratio 
would result in the selection of significantly divergent number of compounds for each species: 
L. amazonensis (61), L. braziliensis (39) and L. donovani (31). The great difference in the 
number of compounds selected for each specie diffilcults the comparasion of results. The 
selection based on positive controls (infected cells treated with 10µM amphotericin B) standard 
deviations led to a similar trend. Hence, aiming to correlate compounds activity among species 
latter, selection of the forty most active compounds with cell ratio ≥0.5, approximately 3% of 
the library, was a better option. The L. amazonensis was the most sensitive species, with the 40 
selected compounds presenting mean activity of 81.5 %, followed by L. donovani and L. 
braziliensis, 63.5 and 61.5%, respectively. In total, with no duplication, 71 compounds were 
chosen for be assessed in dose-response curve, from which only 27 (38%) were selected in all 
three models. 
The therapeutic profile of selected compounds was compared with the general 
library distribution of pharmacological classes. Within the ten therapeutic categories 
(classification provided by supplier support datasheet) drugs related with neurotransmission 
showed the most expressive percentage (70%) for the selected compounds, followed by 
phosphorylation (8%), ion channels (7%), apoptosis/cell cycle (6%), and gene regulation (3%). 
Only within the hormones class no compound was selected. As can be better observed in Figure 
4.24, the selected compounds were quite representative of the library general diversity. 
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Figure 4.24 Therapeutic profile of LOPAC selected compounds. Classes 
frequency distribution of LOPAC and selected compounds from primary 
screening.  
As mentioned in the introduction, drug repurposing is an appealing alternative to 
find new antileishmanial compounds. In this context, several medicines involved with 
neurotransmission have been tested against Leishmania models. Among them, clomipramine 
(Zilberstein and Dwyer 1984), cyclobenzaprine (Cunha-Júnior et al. 2017), sertraline (Lima et 
al. 2018), imipramine (Zilberstein and Dwyer 1984), mianserin (Dinesh et al. 2014), ketanserin 
(Singh et al. 2014) and domperidone (Gómez-Ochoa et al. 2009). Such compounds were 
present in the LOPAC set, and Table 4.7 shows the results of the primary screening for them. 
Table 4.7 Compounds related with neurotransmission reported as active against Leishmania spp. 
Name 
PubChem 
CID 
L. a  L. b  L. d   
NA CR  NA CR  NA CR Reference 
Clomipramine 68539 101 0.8 
 
73.5 0.8 
 
87.1 1.2 
(Zilberstein and 
Dwyer 1984) 
Cyclobenzaprine 22576 83.4 1.0 
 
43.1 0.9 
 
37.1 1.1 
(Cunha-Júnior et 
al. 2017) 
Imipramine 8228 52.8 1.0 
 
19.0 1.0 
 
19.2 1.2 
(Mukherjee et al. 
2012)  
Sertraline 63009 17.6 0.1 
 
34.8 0.0 
 
62.9 0.2 (Lima et al. 2018) 
Mianserin 68551 9.5 1.0 
 
12.9 1.1 
 
0.7 1.1 
(Dinesh et al. 
2014) 
Ketanserin 135348 5.5 1.0 
 
-7.7 1.2 
 
6.9 1.0 
(Singh et al. 
2014) 
Domperidone 3151  9.1 1.1 
 
14.8 1.2 
 
-12 1.0 
(Gómez-Ochoa et 
al. 2009) 
The results obtained in this study are displayed. aNA: Normalized Activity (%); bCR: Cell Ratio. The values are 
mean of two independent experiments. Green color indicates compounds that presented normalized activity 
>40 and cell ratio >0.5. Red color indicates compounds with cell ratio < 0.5. 
Clomipramine was the only compound with broad-spectrum activity for the tested 
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species. This tricyclic antidepressant drug has reported antileishmanial activity against 
amastigotes of L. major and L. donovani within peritoneal macrophages from BALB/c mice 
(pEC50 of 5.9 and 6.22 , respectively) (Zilberstein and Dwyer 1984). Cyclobenzaprine, another 
tricyclic antidepressant, demonstrated pEC50 of 4.9 in intracellular amastigotes of L. infantum, 
also in a model with peritoneal macrophages collected from BALB/c mice (Cunha-Júnior et al. 
2017). But, in the present study, cyclobenzaprine was active only against L. amazonensis and 
L. braziliensis. Imipramine, also a tricyclic antidepressant, has demonstrated in vitro activity 
against L. donovani intracellular amastigotes using peritoneal macrophages from BALB/c mice 
as host cells (pEC50 of 4.8), and when administered orally it was found to be active against both 
antimony sensitive and antimony resistant clinical isolates in a hamster model (Mukherjee et 
al. 2012). However, only L. amazonensis was susceptible to imipramine in the experiments here 
reported. The mode of action of these compounds have been linked to inhibition of 
trypanothione reductase, a key enzyme in the redox metabolism of pathogenic trypanosomes 
(Pandey et al. 2015). 
Sertraline, another well-known antidepressant, has a tetrahydronaphthalene core as 
a chemical scaffold, and has been reported as active against intramacrophage L. infatum (pEC50 
of 5.4) and L. donovani (pEC50 of 5.1) using peritoneal macrophages from BALB/c mice as cell 
hosts (Lima et al. 2018; Palit and Ali 2008). This drug has been also reported as effective in 
eliminating splenic (72%) and liver (70%) parasite loads in BALB/c mice infected with L. 
donovani (Palit and Ali 2008). Unexpectedly, in the present study, sertraline was toxic for THP-
1 cells, impairing the assessment of its activity for all three tested species. Lima and 
collaborators reported that sertraline induce respiration uncoupling, a significant decrease of 
intracellular ATP level, and oxidative stress in L. infantum promastigotes (Lima et al. 2018). 
The other three drugs were ineffective against all tested species here reported. 
Mianserin, a tetracyclic antidepressant, has reported activity against L. donovani infected THP-
1 cells (pEC50 of 4.3), with its mode of action via depletion of ergosterol levels (Dinesh et al. 
2014). Ketanserin, a tricyclic serotonin S2-receptor antagonist, which is used as 
antihypertensive agent, has been tested against L. donovani infected THP-1 cell (pEC50 of 4.6), 
and observations suggest that its lethal effect is due to inhibition of 3-hydroxy-3-methylglutaryl 
coenzyme A reductase (HMGR) (Singh et al. 2014).  
On the other hand, the lack of in vitro antileishmanial activity for domperidone was 
not surprising, since the therapeutic use of this drug has been proposed as an 
immunomodulation approach (Gómez-Ochoa et al. 2009). Domperidone is a gastric prokinetic 
and antiemetic drug and is also a selective dopamine D2 receptor antagonist. The drug, as a 
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secondary effect, stimulates prolactin production due to release of serotonin. The prolactin is a 
hormone that stimulates milk production in mammals, and plays a central role in the immune 
system as a pro-inflammatory cytokine. It stimulates a protective CD4 + Th1cell-mediated 
immune response by increasing the production of INF-γ, IL2, IL12, and TNF-α; which would 
help dogs to control and reduce clinical signs, and decrease anti-Leishmania antibody titers 
(revised in Travi and Miró 2018).  
In order to evaluate how similar is the LOPAC screening activity among species, 
the correlation between activity of paired species was measured by the Pearson-coefficient, 
represented by the lowercase letter ‘r’. This parameter is a statistical measure that can show 
whether, and how strongly, pairs of variables are related. It is expressed as values between +1 
and -1. A perfect positive correlation between variables is indicated by +1 value. Conversely, a 
perfect negative correlation (when variable increases and the other decreases) is represented by 
-1 value. The zero indicates there is no discernable relationship. As can be seen in Figure 4.25 
A, regarding LOPAC compounds, there was a strong correlation for all species pairing, with 
the highest value of Pearson-coefficient for L. amazonensis x L. braziliensis (0.76), followed 
by L. amazonensis x L. donovani (0.74) and L. braziliensis x L. donovani (0.68). However, the 
majority of compounds did not present activity (or presented only a marginal score) against 
parasites, which bias the index. When the same analysis is performed with the 71 selected 
compounds, there was low or none correlation in all cases (Figure 4.25 B). These results 
highlight the discrepancy of compounds activity for different species, which has an impact on 
the selection of compounds from a primary screening. 
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Figure 4.25 Differential activity of LOPAC compounds for Leishmania species. Plots show the 
compounds activity correlation between paired species. A) 1280 LOPAC compounds B) 71 selected 
compounds from primary screening. 
The next step was to determine compounds potency. Two independent dose-
response experiments were carried out. On account of limited compound availability, the top 
tested concentration was 50 µM. From the 71 compounds, it was possible to determine EC50 
values for 51. Figure 4.26 summarizes the results obtained for the LOPAC screening. The 
overall compound potency was only marginal against Leishmania parasites, most compounds 
presented EC50 values higher than 30 µM, meaning pEC50 around 4.5 or lower. Inspection of 
maximum activity and pEC50 data, reported in Table 4.8, indicates as few as 14 (27.5%) broad-
spectrum candidates out of the 51. Other 14 (27.5%) shared activity between two species and 
23 (45%) were species-specific.  
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Figure 4.26 Summary of LOPAC screening against Leishmania spp. species. After primary 
screening at single-point concentration (50 µM), the 40 most active compounds with cell ratio (CR) 
greater than 0.5were tested in dose-response curve (DRC) for activity confirmation. The compounds 
with determined EC50 values were used to plot the Venn Diagram. 
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Table 4.8 LOPAC compounds maximum activity and pEC50 values 
# 
   Max. Activity (%)   pEC50 M 
PubChem 
CID   
L. a L. b L. d  L. a L. b L. d 
1 89105    70 78 78   4.51 5.66 5.43 
2 11957564   100 80 93   4.54 4.49 4.59 
3 68539     101 81 75   4.44 4.52 4.58 
4 71478   91 72 85   4.44 4.50 4.56 
5 6603149   100 82 58   4.41 4.43 4.53 
6 108047     96 89 76   4.45 4.48 4.41 
7 11957654    101 64 60   4.34 4.54 4.36 
8 11957471     98 71 93   4.40 4.38 4.44 
9 9823846   87 70 62   4.44 4.41 4.36 
10 9803932   80 86 57   4.59 4.39 4.36 
11 5282318   76 59 50   4.40 4.55 4.39 
12 122824    86 64 44   4.34 4.43 4.50 
13 11957725   83 62 59   4.37 4.58 4.31 
14 6438352   78 71 52   4.38 4.42 4.31 
15 2585   100 61    4.45 4.79  
16 65327   80 75     4.56 4.49   
17 238053   73 72     4.49 4.54   
18 11957719   64 66     4.55 4.46   
19 24351   80 70     4.46 4.51   
20 441358     82 63    4.53 4.44  
21 2820    95 79    4.42 4.52  
22 2170   89 63     4.42 4.51   
23 13770     84 73    4.53 4.39  
24 67356    96   82   4.42   4.42 
25 31100     92 57     4.43 4.41   
26 6014    81 70     4.40 4.40   
27 71311765   77 75    4.40 4.34   
28 2818   61 60     4.31 4.39   
29 10314472       77       4.74 
30 11723708    77       4.62     
31 909822     59       4.59   
32 66062       81       4.58 
33 71420        87       4.57 
34 148177       66       4.56 
35 4748        77       4.56 
36 66069         84       4.55 
37 60839     94       4.54     
38 62878       76       4.50 
39 28693        80       4.49 
40 3039995        87       4.47 
41 133633       58       4.46 
42 5282483       88       4.46 
43 66064        87       4.42 
44 11957588     57       4.41   
45 6918119     94       4.40   
46 2858523        72       4.35 
47 5887     67      4.34   
48 672296       62       4.33 
49 11973707   64       4.31     
50 11225543   76       4.30     
51 65341   71       4.30     
Max. Activity is the mean value of normalized activity percentage at 50 µM of four independent 
experiments. pEC50 is the mean value of two independent experiments. Colors code: max. activity 
> 90% (green), 70% < max. activity < 90% (orange) and max. activity < 70% (grey). Blank represent no 
activity. pEC50 = -log EC50 (M).  
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 Pathogen Box library 
The Pathogen Box library (Pbox) was tested at single-point concentration of 20 µM 
against L. amazonensis, L. braziliensis, L. donovani and L. infantum. Table 4.9 shows the 
screening statistics data for each species. 
Table 4.9 Pathogen Box primary screening quantitative data 
 L. amazonensis L. braziliensis L. donovani L. infantum 
Z’-factor 0.63±0.01 0.63±0.01 0.65±0.04 0.79±0.03 
IR - 0.5% DMSO 50.60 ± 4.33 64.46±4.78 79.89±5.25 83.65±3.50 
IR - Non-infected 6.81 ± 1.76 9.56±2.36 10.10±2.45 5.27±1.55 
Values expressed as Mean ± Standard Deviation 
All models presented a satisfactory window between negative and positive controls, 
which resulted in Z’-factor values greater than 0.6 for all assay plates: 0.63 for L. amazonensis, 
0.63 for L. braziliensis, 0.65 for L. donovani and 0.79 for L. infantum. 
Analysis of general compounds distribution per normalized activity showed that 
more than 80.2% (± 7.8) of compounds were completely inactive against Leishmania spp, and 
only 3.6 % (± 0.4) presented activity higher than 75% (Figure 4.27 A). 
The support information of PBox clusters the compounds according to the 
antiparasitic activity firstly described. Seventy compounds within the PBox have been reported 
as active against L. donovani, T. b. brucei and/or T. cruzi, and are grouped within a single set 
(kinetoplastids). The twenty most active compounds (approximately 10% of the library) for 
each species were selected to evaluate their distribution within these groups, adding up to 41 
compounds (without duplications) (Figure 4.27 B). Most of the compounds selected were 
within the tuberculosis group (29%), followed by kinetoplastids (27%) and Malaria (20%). 
Furthermore, 7 reference compounds were within the selected list, which correspond to 17%. 
The reference set within PBox is composed of 26 compounds from which 7 have 
reported antileishmanial activity, including drugs used in current therapeutics: amphotericin B, 
miltefosine, pentamidine, nifurtimox, clofazimine, sitamaquine and buparvaquone. The in-
library amphotericin B, miltefosine and sitamaquine were inactive for all species. Pentamidine 
was active against L. amazonensis (activity of 60%) and Nifurtimox against L. braziliensis 
(82%). Clofazimine was effective against visceral agents, L. donovani (95%) and L. infantum 
(62%). Only buparvaquone presented broad-spectrum activity: L. amazonensis (106 %), L. 
braziliensis (104 %), L. donovani (97 %) and L. infantum (89 %). The ineffectiveness of 
amphotericin B and miltefosine within the PBox is not a point of concern, because compound 
degradation may occur with the repeated thawing-freezing cycles, and the in-house controls of 
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both compounds, tested in the same assay as dose-response curves, were active as expected. 
Similar issue has been reported in the PBox screening by Duffy et al. 2017. 
 
Figure 4.27 Profile of PBox screening. A) General distribution of all 400 compounds per normalized 
activity against Leishmania species. X-axis shows the binned normalized activity of compounds and 
Y-axis shows the frequency in percentage. B) General distribution of all PBox compounds in diseases 
sets (black) and the 41 most active compounds selected in the Leishmania spp. screening (white). X-
axis shows the antiparasitic categories and Y-axis shows the frequency in percentage. 
Regarding correlations between paired species, on the whole there was a 
considerable correlation for the PBox library (r = 0.62 ± 0.08), which is not surprising due to 
the substantial percentage of inactive compounds (Figure 4.28 A). In contrast, the correlation 
data for the 41 selected compounds varied depending on the species pair (Figure 4.28 B). The 
L. donovani/L. infantum pair maintained a high correlation coefficient (r = 0.74). The same 
occurred to L. amazonensis/L. donovani (r = 0.51). The complete loss of correlation was noticed 
only to L. braziliensis paired with L. donovani and L. infantum. 
The maintenance of correlation between some pair of species for the most active 
compounds of the PBox contrasts with the results for LOPAC screening, for which no 
correlation at all was found between the species. This conflicting outcome highlights the impact 
of the library composition in the correlation. The LOPAC is a commercial library without any 
focus on leishmaniasis. In contrast, the PBox is an open access collection constituted by 17.5% 
of active compounds against kinetoplastid parasites and 6.5 % of reference compounds. 
Additionally, the PBox has one third of compound numbers (400) when compared with the 
LOPAC (1200). Thus, as bigger and less focused the compound collection is, the more 
divergent the selection of compounds will be for different species of Leishmania, and that also 
likely increases the chance of selection of species-specific molecules over broad-spectrum ones 
in single model platforms.  
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Figure 4.28 Differential activity of the PBox compounds for Leishmania species. Plots show the 
compounds activity correlation between paired species. A) 400 PBox compounds B) 31 selected 
compounds from primary screening. 
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Table 4.10 compares each species normalized activity of all 41 most active selected 
compounds. In view of the fact that the PBox was tested once at single concentration, 
compounds with normalized activity greater than 40% were considered actives.  
 Table 4.10 PBox most active compounds list 
# MMV ID PubChem CID L. a L. b L. d L. i 
1 MMV689480 71768   106 104 97 89 
2 MMV689437 129011774 111 102 93 87 
3 MMV021660 44523242 99 84 100 97 
4 MMV688262 6480466 108 84 93 94 
5 MMV690102 122196562 102 90 94 85 
6 MMV688279 129011770 87 85 100 86 
7 MMV011903 3110698   95 96 70 82 
8 MMV690103 122196561 69 85 96 89 
9 MMV687765 70695572 77 70 74 86 
10 MMV687807 71508634 72 97 69 64 
11 MMV675968 461917 67 90 85 43 
12 MMV1030799 17399080 -3 96 85 90 
13 MMV688372 72710598 87 56 73 50 
14 MMV688978 24199313 63 60 80 56 
15 MMV637229 68896369 25 95 91 41 
16 MMV676477 8518466 100 89 35 21 
17 MMV687749 122196546 25 83 43 58 
18 MMV688991 41684 98 23 38 35 
19 MMV676512 16360478 54 82 15 41 
20 MMV676558 7354360 75 80 18 17 
21 MMV658988 12004233 -17 78 67 62 
22 MMV676401 644385 24 54 74 29 
23 MMV595321 18568993 27 85 35 34 
24 MMV023233 44525694 -4 28 74 80 
25 MMV687730 50994378 -1 25 81 65 
26 MMV687800 2794 -4 8 95 61 
27 MMV026550 44530521 55 88 10 -2 
28 MMV688467 23627030 61 43 37 9 
29 MMV024311 129011762 -4 42 88 21 
30 MMV000062 4735 60 38 32 15 
31 MMV011511 24732616 -4 48 74 21 
32 MMV688283 122196557 -11 88 30 30 
33 MMV688514 16658982 5 26 72 31 
34 MMV687776 129011775 80 26 18 7 
35 MMV688990 3599 -4 0 90 30 
36 MMV024406 44527543 -13 2 37 85 
37 MMV001499 6604371 0 82 22 1 
38 MMV676057 23656964 0 83 6 5 
39 MMV019790 7080312 8 11 9 55 
40 MMV023388 129011766 -12 20 27 45 
41 MMV688755 456199 -22 93 -1 8 
 Values of activity were classified by colors: activity > 80% (green), 
40 < activity < 80 (yellow) and activity < 40% (red). 
Thirteen molecules (31.7%) presented species-specific activity, other 10 (24.39%) 
were active against two species, and 18 (43.9%) against three or four species (Figure 4.29). 
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Figure 4.29 Venn Diagram comparing the selected compounds for each 
specie. Each colour represents the twenty most active compounds for one species. 
The PBox supporting information lists 27 compounds that were reported with 
pEC50 > 4.7 (EC50 < 20 µM) for intracellular L.infantum in murine primary cells. Table 4.11 
lists such compounds, their pEC50 and the obtained results for them in the present study. 
Table 4.11 Compounds within PBox supporting information with pEC50 > 4.7 
MMV ID 
*L. infantum 
pEC50 
L. a L. b L. d L. i 
aNA bCR NA CR NA CR NA CR 
MMV690102 7.5 102 1.3 90 1.0 94 0.8 85 0.7 
MMV688372 6.7 87 0.7 56 0.4 73 0.6 50 0.5 
MMV690103 6.3 69 1.2 85 1.0 96 0.9 89 0.9 
MMV689437 6.3 111 1.3 102 0.8 93 0.8 87 0.5 
MMV688371 6.2 32 0.7 86 0.0 102 0.1 91 0.1 
MMV676602 6.0 28 0.4 57 0.5 67 0.2 47 0.1 
MMV688179 6.0 -15 1.1 19 0.8 52 0.7 21 0.7 
MMV688180 6.0 51 1.0 38 1.1 39 1.3 6 0.8 
MMV676604 5.9 50 0.0 63 0.0 78 0.1 70 0.1 
MMV652003 5.9 38 0.7 73 0.7 60 0.7 24 0.7 
MMV689061 5.8 -20 1.0 26 1.0 9 1.0 0 0.9 
MMV688283 5.6 -11 1.1 88 0.8 30 1.1 30 1.0 
MMV688514 5.6 5 1.0 26 1.0 72 1.0 31 1.0 
MMV659004 5.4 -23 1.0 82 0.4 6 1.0 20 0.7 
MMV658988 5.4 -17 1.2 78 0.4 67 0.5 62 0.7 
MMV676600 5.4 -9 0.8 40 0.9 20 0.5 0 0.8 
MMV687706 5.4 -11 1.0 73 1.1 69 1.2 13 1.0 
MMV688279 5.4 87 1.0 85 0.8 100 0.9 86 1.0 
MMV595321 5.2 27 0.7 85 1.0 35 0.9 34 0.9 
MMV688410 5.0 3 1.1 25 1.1 28 0.9 1 0.9 
MMV676057 5.0 0 1.2 83 1.2 6 1.2 5 1.0 
MMV688271 5.0 -16 1.1 8 1.1 17 1.0 5 0.8 
MMV001561 4.9 -16 1.1 9 1.1 54 1.1 37 1.0 
MMV688467 4.9 61 0.9 43 0.7 37 1.1 9 0.9 
MMV676048 4.8 -11 0.9 3 1.0 5 0.9 0 0.9 
MMV659010 4.8 -12 1.1 16 1.1 26 1.0 -7 1.1 
MMV688415 4.8 -27 1.0 2 1.0 23 1.2 9 1.0 
*In grey the pEC50 values reported in the supporting information onbtainded in the Laboratory of 
Microbiology, Parasitology and Hygiene (LMPH), Univ. of Antwerp are shown. The other columns are 
the results obtained in this study. aNA: Normalized Activity (%); bCR: Cell Ratio. Green color indicates 
compounds that presented normalized activity >40 and cell ratio >0.5. Red color indicates compounds 
that presented cell rate < 0.5. pEC50 = -log EC50 (M). 
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Table 4.11 inspection reveals that only five compounds (18.52%) presented 
normalized ≥ 40% activity and ≥ 0.5 cell ratio for all species. Still, 12 compounds (44%) were 
active against at least one representant without cell toxicity. 
The Pathogen Box has been also screened against L. donovani THP-1 infected cells 
in an HCS assay more or less similar to the protocol here reported (Duffy et al. 2017). Table 
4.12 displays pEC50 values of the 16 most potent compounds identified by the study and the 
results obtained in the present study. From which 9 (56%) were active in at least one model, 
with cell ratio ≥ 0.5, being 5 (31.25 %) active against at least 3 species.  
Table 4.12 Activity of the 16 most potent PBox compounds reported by (Duffy et al. 2017) 
 *L. donovani 
pEC50 
L a L. b L d L i 
MMV ID aNA bCR NA CR NA CR NA CR 
MMV690102 6.3 102 1.4 90 1.0 94 0.8 85 0.7 
MMV652003 5.9 38 0.7 73 0.7 60 0.7 24 0.7 
MMV676602 5.8 28 0.4 57 0.5 67 0.2 47 0.1 
MMV021013 5.8 66. 0.1 69 0.1 34 0.5 55 0.4 
MMV688372 5.8 86. 0.7 56 0.4 73 0.6 50 0.5 
MMV688763 5.7 100. 0.1 62 0.2 29 0.5 24 0.4 
MMV688271 5.5 -16 1.1 7.7 1.1 17 1.0 5 0.8 
MMV687273 5.5 74 0.0 82 0.0 109 0.1 100 0.1 
MMV676604 5.3 51 0.0 63 0.0 78 0.1 70 0.1 
MMV022478 5.3 104 0.0 100 0.0 111 0.1 95 0.1 
MMV022029 5.3 61 0.2 59 0.1 87 0.2 88 0.1 
MMV687807 5.3 72 0.8 96 0.8 69 0.2 64 0.2 
MMV010576 5.3 49 0.9 64 0.8 53 1.1 6 0.8 
MMV690103 5.3 69 1.2 85 1.0 96 0.9 89 0.9 
MMV688768 5.3 68 0.0 65 0.1 61 0.5 4 0.7 
MMV689437 5.2 11 1.3 102 0.8 93 0.8 87 0.5 
*In grey the pEC50 values reported by (Duffy et al. 2017) are shown. The other columns are the results 
obtained in this study. aNA: Normalized Activity (%); bCR: Cell Ratio. Green indicate compounds that 
presented normalized activity ≥ 40 and cell ratio ≥ 0.5. Red indicate compounds that presented cell rate 
< 0.5. pEC50 = -log EC50 (M). 
 
Analyzing the values of normalized activity and cell ratio for the same compounds 
reported by Duffy et al., it was noticed that most of them were cytotoxic for THP-1 cells. But 
it is worth pointing out that Duffy et al. have not reported the toxicity on infected THP-1 cells 
for the tested molecules. They reported toxicity data relative to a viability assay against HEK 
cells. It is certainly of most importance further investigation of toxicity in a panel of uninfected 
cells. But the bias of evaluating activity of a compound that, in addition to reducing infection 
rate and parasitic load, also significantly decreases the number of host cells cannot be ignored 
in intracellular assays. When a compound has toxic effect on the cell, it is impossible to 
distinguish whether the activity against the intracellular parasite is a consequence of host cell 
(upcoming) death or a direct effect of the compound; therefore, in these cases the activity data 
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are not reliable. The viability of the infected and treated cell is a crucial step in avoiding the 
selection of non-selective compounds. This is the major advantage of HCS methodology, the 
power of simultaneously providing critical and quantitative information for each tested 
compound concerning amastigote load and toxic effects on host cell at the single cell level, and 
such data must be included in all reports. 
More recently, the PBox was tested against both axenic and intracellular 
amastigotes of L. mexicana expressing the luciferase NanoLuc-PEST (Berry et al. 2018). The 
most potent identified compounds are listed in Table 4.13. All seven compounds were active 
against at least one species here tested, and did not present toxicity against THP-1 cells. 
Additionally, 4 compounds presented broad-spectrum activity. 
Table 4.13 Activity of the 7 most potent PBox compounds reported by (Berry et al. 2018) 
MMV ID 
*L. mexicana pEC50 L a L. b L d L i 
Axenic Intra. aNA bCR NA CR NA CR NA CR 
MMV676477 7.2 5.3 100 0.7 89 0.7 35 0.9 21 0.8 
MMV652003 7.1 5.4 38 0.7 73 0.7 60 0.7 24 0.7 
MMV011903 6.7 5.7 95 1.0 96 1.0 70 0.5 82 0.2 
MMV689480 8.7 6.4 106 1.3 104 1.2 97 0.8 89 0.9 
MMV595321 6.8 5.3 27 0.7 85 1.0 35 0.9 34 0.9 
MMV690102 7.2 7.0 102 1.4 90 1.0 94 0.8 85 0.7 
MMV688262 7.5 5.7 108 0.8 84 0.9 93 0.7 94 0.7 
*In grey the pEC50 values reported by (Berry et al. 2018) are shown. The other columns are the results 
obtained in this study. aNA: Normalized Activity (%); bCR: Cell Ratio. pEC50 = -log EC50 (M). Green color indicates 
compounds that presented normalized activity ≥ 40 and cell ratio ≥ 0.5.  
When all the compounds with reported antileishmanial activity from Tables 4.11, 
4.12 and 4.13 are analyzed together, after removing duplications, there are 39 compounds. A 
disappointing number of 9 (23%) was found to have activity against at least 3 of the species 
here tested. This find is quite unsettling, since these 39 compounds are considered starting 
points for drug discovery and development, including modification of the compounds guided 
by medicinal chemistry and target identification, by the scientific community. 
Most of the available assays rely on a single endpoint determination of compound 
potency against only one Leishmania species/strain. As a consequence of the sophisticated 
Leishmania spp cycle, is not feasible to standardize a single biological assay that perfectly 
represents the physiopathology, and at same time enables the prospection of great collections 
of samples. The better option is to expand the arsenal of relevant secondary assays. Such assays 
empower the prioritization of compounds based on crucial aspects besides the filters 
traditionally applied (mainly physico-chemical properties and toxicity). Thus, accelerating the 
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progression of best compounds.  It is important to include recent isolates of Leishmania 
species/strains from the field for in vitro as well as in vivo tests, avoiding selection of hits 
against laboratory-adapted parasites (Hefnawy et al. 2018). Although it is known that reference 
isolated organisms present consistency and uniformity, Leishmania virulence fluctuates over 
time after several in vitro passages (Miguel et al. 2011; Zauli-Nascimento et al. 2010). 
Additionally, assessment of the minimal exposure time required to exert full antileishmanial 
activity, also known as “time-kill” assay, has been reported ( et al.; Maes et al. 2017; Tegazzini 
et al. 2017) and should be considered a trend for future in vitro assays. Unraveling the relation 
of the time-kill assay to drug resistance and treatment outcome can be a powerful tool to 
prioritize selected drug candidates. Finally, neither human cell lines or primary murine cells 
fully mimic human origin primary macrophages, the ideal in vitro model. Additionally, 
antileishmanial activity of compounds can be dependent of the host cell (Seifert et al. 2010). 
Thus, the test in peripheral blood mononuclear cells (PBMCs) is important to eliminate cell-
specific compounds. 
On the whole, based on our results and recent reports, here we highlight four 
imperative secondary in vitro assays to assist compounds prioritization in early drug discovery: 
(i) broad-spectrum activity evaluation; (ii) activity against drug-resistant clinical isolates; (iii) 
evaluation of the rate of action; and (iv) activity in human primary cells (Figure 4.30). 
 
Figure 4.30 Cell-based assay cascade for Leishmania spp. in early drug discovery. 
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 Pan-antileishmanial compounds 
Taking in account data from both libraries (LOPAC and PBox), 32 compounds 
presented broad-spectrum activity against three or four species. Their molecular structures are 
displayed in Figures 4.31 and 4.32, and Table 4.14 shows their normalized activity at 20 µM. 
Confronting Table 4.8, which display LOPAC compounds normalized activity at 
50 µM, and Table 4.14, it is clear that most LOPAC compounds were active only at 50 µM, 
presenting a marginal activity at 20 µM. Only CB1954 (PubChem CID 89105), a 
nitroheterocyclic prodrug, previously reported as an antitrypanosomatidic agent (Voak et al. 
2013, 2014; Bot et al. 2010), demonstrated a persistent broad-spectrum activity at 20 µM. 
Table 4.14 List of compounds with broad-spectrum activity 
# Library PubChem CID L. a L. b L. d L. i Mean 
1 PBox 71768 106 104 97 89 99 
2 PBox 129011774 111 102 93 87 98 
3 PBox 44523242 99 84 100 97 95 
4 PBox 6480466 108 84 93 94 95 
5 PBox 122196562 102 90 94 85 93 
6 PBox 129011770 87 85 100 86 89 
7 PBox 3110698 95 96 70 82 86 
8 PBox 122196561 69 85 96 89 85 
9 PBox 70695572 77 70 74 86 77 
10 PBox 71508634 72 97 69 64 75 
11 PBox 461917 67 90 85 43 71 
12 LOPAC 89105  49 82 73   68 
13 PBox 17399080 -3 96 85 90 67 
14 PBox 72710598 87 56 73 50 67 
15 PBox 24199313 63 60 80 56 65 
16 PBox 68896369 25 95 91 41 63 
17 PBox 122196546 25 83 43 58 52 
18 PBox 16360478 54 82 15 41 48 
19 PBox 12004233 -17 78 67 62 47 
20 LOPAC 11957564 24 34 37   32 
21 LOPAC 108047   38 21 22   27 
22 LOPAC 68539   31 35 7   24 
23 LOPAC 71478 2 36 29   22 
24 LOPAC 9823846 37 21 0   19 
25 LOPAC 11957725 19 28 4   17 
26 LOPAC 6603149 17 21 3   14 
27 LOPAC 9803932 26 11 1   12 
28 LOPAC 11957471   3 18 13   11 
29 LOPAC 5282318 5 19 7   10 
30 LOPAC 6438352 9 14 4   9 
31 LOPAC 122824  1 12 14   9 
32 LOPAC 11957654  3 8 5   5 
Heat map of normalized activity at 20 µM. Blank indicates the compound was 
not tested for L .infantum. 
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Figure 4.31 Molecular structure of compounds with broad-spectrum activity (1-16). 
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Figure 4.32 Molecular structure of compounds with broad-spectrum activity (17-32). 
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Nitroheterocyclic drugs are structurally characterized by one or more nitro 
substituents attached to an aromatic ring. Among the expressive variety of indications for 
protozoan and bacterial (anaerobic) infections, nitroheterocyclic molecules have been assessed 
as potential antileishmanial candidates. For instance, fexinidazole, the oral treatment recently 
recommended by the European Medicines Agency (EMA) for sleeping sickness (DNDi 2018a), 
has been tested in a phase II clinical trial against visceral leishmaniasis, but it failed to 
demonstrate efficacy in patients (Musa and Khalil 2015). Delamanid, a nitro-dihydro-
imidazooxazole derivative formerly reported as antimycobacterial agent, has been shown to be 
effective against leishmania (Patterson et al. 2016). Additionally, a nitroimidazole backup of 
VL-2098 compound (DNDi-0690) is under clinical trial phase I (DNDi 2018b). 
In order to identify an explorable scaffold for further optimization, the similarity 
index of the compounds chemical structure was calculated (Figure 4.33). 
 
Figure 4.33 Heatmap based on chemical structure similarity determined by Tanimoto 
coefficient. The axes show the PubChem CID. Tanimoto similarity coefficient was calculated using 
(http://chemminetools.ucr.edu). 
 
The analysis of compounds’ chemical structures similarities did not reveal any 
cluster, only four pairs of compounds with Tanimoto similarity coefficient greater than 0.5 were 
identified: 70695572/122196546 (0.83); 108047/9803932 (0.83); 71478/6603149 (0.62); and 
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68539/5282318 (0.58). 
Overall, PBox compounds were the most active (see Table 4.14). Taking into 
consideration activity for all four species, it was considered pan-antileishmanial compounds 
those which presented activity greater than 70% for all species in this study, without cell 
toxicity. A second analysis considered also as pan-antileishmanial compounds those that 
presented activity greater than 40% for at least three species in this study and potency 
determined by at least one of the following reported studies: Pbox supporting information data, 
Duffy et al. 2017 or Berry et al. 2018. Accordingly, 12 pan-antileishmanial compounds were 
identified (Table 4.15). 
Table 4.15 Pan-antileishmanial compounds 
MMV ID 
L. a L. b L. d L. i cL. i dL. d eL. m 
aNA bCR NA CR NA CR NA CR pEC50 pEC50 pEC50 
MMV689480 106 1.3 104 1.2 97 0.8 89 0.9 - - 6.4 
MMV689437 111 1.3 102 0.8 93 0.8 87 0.5 6.3 5.2 - 
MMV021660 99 1.1 84 0.6 100 1.0 97 0.9 - - - 
MMV688262 108 0.8 84 0.9 93 0.7 94 0.7 - - 5.7 
MMV690102 102 1.3 90 1.0 94 0.8 85 0.7 7.5 6.3 7.0 
MMV688279 87 1.0 85 0.8 100 0.9 86 1.0 5.4 - - 
MMV011903 95 1.0 96 1.0 70 0.5 82 0.2 - - 5.7 
MMV690103 69 1.2 85 1.0 96 0.9 89 0.9 6.3 5.3 - 
MMV687765 77 1.1 70 0.7 74 0.9 86 0.9 - - - 
MMV688372 87 0.7 56 0.4 73 0.6 50 0.5 6.7 5.8 - 
MMV652003 38 0.7 73 0.7 60 0.7 24 0.7 5.9 5.9 5.4 
MMV010576 49 0.9 64 0.8 53 1.2 6 0.8 - 5.3 - 
aNA: Normalized Activity (%); bCR: Cell Ratio. Green color indicates compounds that presented 
normalized activity ≥ 70 and cell ratio ≥ 0.5. In grey the pEC50 values reported by  c PBox supporting 
information; d  Duffy et al. 2017 and e Berry et al. 2018 are shown.. pEC50 = -logEC50 (M).  
Representative images of infected cells treated with each of the 12 pan-
antileishmanial compounds are shown in the Appendix 2. 
Buparvaquone (MMV689480), an antiprotozoal drug related to primaquine 
hydroxynaphthoquinone and atovaquone, was found to be the most effective compound in this 
study, with mean activity of 99% for all species. Croft et al. (Croft et al. 1992) demonstrated 
for the first time the in vitro activity of buparvaquone against L. donovani; however, the drug 
showed limited in vivo efficacy in the BALB/c mouse model. There are some studies attempting 
to improve its efficacy by using liposomal formulations (da Costa-Silva et al. 2017). 
MMV690102, MMV690103 and MMV689437, belonging to the chemical group 
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pyrimido [4,5-d] pyrimidine-2,4,7-triamine, demonstrated activity greater than 85% for all 
tested species. These compounds were previously identified from GSK screening against 
Leishmania, T. cruzi and T. brucei. Structurally related compounds have been shown to be 
dihydrofolate reductase (DHFR) inhibitors isolated from mammals (Gebauer et al. 2003), 
which is potentially the target in kinetoplastid parasites. 
MMV021660, MMV688262 and MMV687765 were previously described as 
inhibitors of M. tuberculosis (Ballell et al. 2013; Li et al. 2014; Palmer et al. 2015). Here, these 
compounds were also active against all four species, with activities greater than 70%. 
MMV688279 showed antitrypanosomal activity against bloodstream forms of T. 
brucei and inhibited the T. brucei recombinant trypanothionein S427 reductase (Patterson et al. 
2011). This compound presented broad-spectrum activity in the presented study, the lowest 
activity was 85%. MMV688372 is a substituted 2-(3-aminophenyl) oxazolopyridines analogue 
and is active against T. brucei. Another analogue of the same series demonstrated efficacy in a 
mouse model of trypanosomiasis (Tatipaka et al. 2014). MMV652003 was able to cure the late-
stage of central nervous system african trypanosomiasis in a murine model when administered 
intraperitoneally or orally (Nare et al. 2010). MMV688372 and MMV652003 presented 
marginal activities for some species in the present study, however their potency was 
demonstrated by others reports (see Table 5.11), therefore, they were also considered pan-
antileishmanial compounds. 
MMV011903 was identified through the development of a class of agents based on 
a polyaromatic pharmacophore structurally related to clotrimazole as an antimalarial (Gemma 
et al. 2008). Here, it was active (>70%) for all Leishmania species. MMV010576 is a 
representative of a novel class of orally active antimalarials, presenting activity against a 
chloroquine-resistant strain (Gamo et al. 2010; Younis et al. 2012). MMV010576 had marginal 
antileishmanial activity in the present report, but had potency reported by Duffy et al. 2017. 
From the 12 pan-antileishmanial compounds, four compounds (MMV690102, 
MMV690103, MMV689437 and MMV011903) were also active against three T. cruzi 
strains:Y, CL Brener and Sylvio (data not shown). Interestingly, MMV690102, MMV690103, 
MMV689437 have activity reported against Leishmania spp., T. cruzi and T. brucei. The 
activity against the three kinetoplastids possibly indicates a conserved molecular/metabolic 
target, since these parasites have many common core metabolic functions (Aslett et al. 2010). 
On the other hand, no report about MMV011903 activity in the extracellular parasite T. brucei 
was found, only for the intracellular parasites Leishmania spp. and T. cruzi, which might 
indicate a mechanism of action related to cell host modulation.  
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5 Final considerations 
Leishmania infections constitute a complex model from biological, ecological, and 
epidemiological point of view. This parasite has multiple strategies to subvert the host defense 
mechanisms and survive in such a harsh intracellular niche (parasitophorous vacuole). Besides, 
these parasites keep evolving, adapting themselves to new environmental and hosts, and 
developing resistance to drugs. In face of such complexity, it is not surprising that the scientific 
community struggles to understand the paradox of Leishmania infection, multiplication in the 
professional phagocytic cells, and to develop efficient therapeutic options.  
The standardization of a Leishmania spp. high content screening assay was a 
laborious and complex process. It is necessary to find a balance between biologically relevant 
infectious system, practicality and reproducibility. The HCS assay here described is based on a 
protocol previously established by our group at the Institute Pasteur Korea in 2010, the first 
HCS reported to Leishmania spp. (Siqueira-Neto et al. 2010).  
Careful standardization was carried out aiming to achieve robustness and 
reproducibility, based on both: (i) the biological model, determining the best condition for 
parasite and host cell culture, infection and drug exposure, and (ii) the image analysis algorithm, 
which after several adjustments was able to provide useful and proper quantitative data for the 
infection models. This semi-automated assay is based on the infection of THP-1 macrophages 
with stationary phase promastigotes. It was demonstrated that, for the purpose of this study, 
Draq5 staining is sufficient for detection of macrophage nuclei, parasite nuclei/kinetoplast, and 
cytosolic delimitation. However, adjustment of specific image analysis settings was required 
for each species. As a result, all models presented significant robustness and reproducibility, as 
observed by high values of Z´-factor, and acceptable agreement between runs data. 
As no reporter gene is required, this assay can be virtually adapted to any in vitro 
infective Leishmania species, including clinical isolates. Despite the advantages of engineered 
parasites in the development and improvement of biological assays, it has been reported that 
genetic modifications can lead to modifications in parasite metabolism, including loss of 
virulence (Rocha et al. 2013). Also, the genetic alteration of parasites could require culturing 
with selection antibiotic for post-transfection selection, which can lead to uncounted 
pharmacological interactions (Dagley et al. 2015). Nevertheless, this image-based assay can 
also be used to assist functional analysis studies of Leishmania spp. transgenic or knockout 
mutants. Targeted mutation approach is a key tool in basic parasite biology, pathogenicity 
mechanisms and drug resistance studies. The new technology for gene editing by Clustered 
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Regularly Interspaced Short Palindromic Repeats (CRISPR) associated gene 9 (Cas9) enables 
rapid large-scale screening of mutant phenotypes in Leishmania spp., thus accelerating the 
characterization of Leishmania genes for new drugs development (Zhang et al. 2017). 
The multi-species high content assay was established for some of the most clinically 
relevant agents: L. amazonensis, L. braziliensis, L. donovani, and L. infantum. This is the first 
time that libraries are concomitantly screened against intracellular models of different 
dermotropic and viscerotropic Leishmania species using image-based phenotypic approach. 
The correlation for compounds activity between paired species showed an 
interesting, but predictable result. As bigger and less focused the compound collection, more 
divergent is the selection of compounds for different species of Leishmania, which also likely 
increases the chance of selecting species-specific molecules over broad-spectrum ones in single 
species platforms. 
The simultaneous screening of the PBox against four Leishmania species along 
with literature data analysis has resulted in the identification of 12 pan-antileishmanial 
compounds, which offer potential starting points for medicinal chemistry. Four of these 
compounds were also active against three T. cruzi strains. 
The low percentage of reported antileishmanial agents with broad-spectrum activity 
demonstrates the potential value of including a panel of species in early steps of the drug 
discovery cascade, but also highlights the challenge of developing pan-antileishmanial agents. 
A multi-species assay is undoubtedly a powerful secondary assay. But, as in all 
experiments, carefully analysis of the results is required, especially when pan-antileishmanial 
compounds are novel entities and present some level of cytotoxicity to the host cell. In such 
cases is necessary to exclude the possibility of selecting Pan-Assay Interference Compounds 
(PAINS). PAINS are recognized by the ability to show activity across a range of assay platforms 
and against a range of proteins, but their bioactivity is attributated to off-target effects, resulting 
in false positives. Importantly, the identification of PAINS requests experimental proofs of 
selectivity, structural PAINS filters solely should not be used (Capuzzi et al. 2017). 
There was no time to further characterize the compounds with activity against one 
or two species. In case of confirmation of their specificity, they also represent potential start 
points to medicinal chemistry. Given to the disease heterogeneity, specie-specific compounds 
are particularly interesting for tegumentary leishmaniasis, especially if they present intrinsic 
chemical properties that are desirable to topical administration formulations. So, beyond 
identification of broad-spectrum compounds, a multi-species assay also assists the 
identification of species-specific molecules. 
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To conclude, the multi-species high content assay here established represents an 
important contribution to Leishmania spp. early drug discovery and the molecules identified 
with broad -spectrum of activity can be further explored as central scaffolds for designing new 
compounds for the treatment leishmaniasis. 
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APPENDIX 1 
Data reported in (Alcântara 2017). 
 
Standardization the best THP-1 cell density for 384-well plates. THP-1 cells were differentiated with 50 ng/mL 
PMA and plated at 3 different densities: 4,000 (left images), 7,000 (middle images) and 10,000 (right images) 
cells/well. After 48 hours of PMA treatment, plates were fixed with 4% PMA and stained with 5 µM Draq 5. 
Images were acquired by Operetta High Content System (Perkim Elmer) and were analysed by Harmony software. 
Arrows indicates cells clusters caused by higher densities of the culture. Magnification: 20x. 
 
 
Effect of PMA removal after cells differentiation. (a) Posteriorly to 48 hours, cells were maintained with (right/ 
PMA (+)) or without (left/ PMA (-)) PMA reagent. Images were acquired 72 h after. Magnification: 20x.(b), (c), 
(d) and (e) Differences between PMA (+) and PMA (-) cultures in the number of cells, the cytoplasm area, the 
cytoplasm ratio width to length and ratio of cellular multiplication, respectively. Asterisks (*) indicate (p<0.0001).  
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APPENDIX 2 
Representative images of the 12 pan-antileishmanial compounds efficacy. A 
representative image for each specie is shown, starting with negative controls (infected cells 
treated with 0.5 % DMSO) and positive controls (10µM amphotericin B). For the tested 
compounds, the normalized activity (upper right) and cell ratio (bottom right) are also shown. 
The images were acquired by the IN Cell Analyzer 2200 system. 
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